Introduction
============

Several types of small noncoding RNAs have been discovered that affect a multitude of biological pathways within the cell. One such class includes microRNAs (miRNAs), short sequences of noncoding single-stranded RNAs that exhibit inhibitory effects on complementary target mRNAs. Research on miRNAs can provide insights into the development, treatment, and monitoring of diseases, including viral diseases. This review aims to provide an overview of recent research characterizing the role of miRNAs during viral infection. We focus on several viruses of clinical importance in order to assess the potential of host- and virus-derived miRNAs as therapeutic targets or biomarkers of disease.

A *biomarker* is an objectively measured indicator that reflects the presence or progression of a particular condition. In addition, biomarkers can be used to monitor the efficacy of treatments for a disease. The discovery and validation of novel biomarkers reduce the time and cost associated with drug development and therefore increase the success rate of translating experimental drugs into clinical therapeutics.[@b1-bmi-suppl.4-2015-025] They are a valuable tool to improve animal models of disease, monitor drug candidate safety and efficacy, and detect changes in the pathological state of a disease. Biological fluids from the local site of pathology, known as proximal fluids, often provide a more accurate assessment of the pathological state. Plasma is often used for biomarker assessment, due to the ease in obtaining it, and thus, any proximal biomarkers that spill over into the bloodstream may prove to be effective biomarkers that are more easily accessible than proximal fluids.

Biogenesis of miRNAs
====================

Several excellent reviews are available that explain the details of miRNA biogenesis.[@b2-bmi-suppl.4-2015-025],[@b3-bmi-suppl.4-2015-025] Most miRNAs are transcribed through the actions of RNA polymerase II from templates found within introns of protein-coding genes or directly from independent genes.[@b3-bmi-suppl.4-2015-025],[@b4-bmi-suppl.4-2015-025] In the cytoplasm, the miRNA guide strand remains associated with Argonaute (Ago) within the RNA-induced silencing complex (RISC), while the complementary strand, referred to as the miRNA\* (star strand) or passenger strand, is degraded. Unlike most cellular miRNAs, certain viral miRNAs can be derived from both strands of the double-stranded miRNA molecule, leading to the convention of naming the strands with -5p or -3p suffixes.

The guide miRNA is the primary mechanism for targeting the RISC complex to mRNAs. Although miRNAs are \~22 nucleotides in length, the mRNA target is generally recognized through complementary base pairing of the seed sequence comprising nucleotides 2--7 at the 5′ end of the miRNA strand.[@b5-bmi-suppl.4-2015-025] Consequently, one miRNA:RISC complex can silence hundreds of mRNAs with complementarity to the same seed sequence, regardless of their translational products. Once bound by the RISC, miRNAs usually target the 3′-untranslated region (UTR) of mRNAs,[@b6-bmi-suppl.4-2015-025] resulting in the repression of translation and/or degradation of the target mRNA.[@b3-bmi-suppl.4-2015-025],[@b7-bmi-suppl.4-2015-025] It is now well established that miRNAs influence an extensive number of biological pathways in this manner through regulation of protein-coding genes.

Techniques for miRNA Identification and Verification
====================================================

Host- and virus-derived miRNAs can be identified computationally using bioinformatics or through functional screening assays. A variety of bioinformatics programs are now available that predict miRNAs ([Table 1](#t1-bmi-suppl.4-2015-025){ref-type="table"}). Although bioinformatics has been extremely valuable in bringing together possible sets of miRNAs and their targets, the advent of relatively inexpensive next-generation sequencing (deep sequencing) platforms and high-density oligonucleotide arrays has simplified the functional screening of viral miRNAs. Most viral miRNAs were initially identified through a modified rapid amplification of cDNA ends protocol. Briefly, polyacrylamide gel-purified small RNAs were modified with 5′ or 3′ oligonucleotides that functioned as primers for PCR after reverse transcription and the amplified segments were cloned and sequenced. Next-generation sequencing techniques have since then replaced the time-consuming process of cloning and can process millions of sequence reads in parallel. An elegant use of this technique to identify biologically relevant miRNAs is termed **hi**gh-**t**hroughput **s**equencing of RNA isolated by **c**ross**l**inking **i**mmuno**p**recipitation (HITS-CLIP). In this process, ultraviolet (UV) irradiation is used to covalently crosslink Ago-associated miRNAs and target mRNAs, which are then immunoprecipitated and sequenced.[@b8-bmi-suppl.4-2015-025] This procedure allows for the identification of miRNAs and their cognate mRNA recognition elements (MREs) that are directly associated with RISC from cell lines or tissue samples.[@b9-bmi-suppl.4-2015-025] **P**hoto**a**ctivatable-**r**ibonucleoside-enhanced **c**ross**l**inking and **i**mmuno**p**recipitation (PAR-CLIP) is a related technique that uses a photoactivatable nucleoside analog, most often 4-thiouridine, which is randomly incorporated into nascent RNAs.[@b10-bmi-suppl.4-2015-025] The stable crosslinking of PAR-CLIP results in increased purification of bound miRNA/mRNA duplexes. However, this technique cannot be performed on primary tissue samples. Both procedures enhance the precision of purified biologically relevant miRNAs and their targets that can then be confirmed *in vitro*.

Following their identification through bioinformatics or high-throughput techniques, putative miRNAs and their targets must be experimentally validated. Luciferase reporter assays are commonly used to verify direct binding of a miRNA to a particular mRNA sequence. The 3′-UTR region predicted to interact with a miRNA target is placed downstream of the luciferase gene in a reporter construct. The vector is then transfected into cells alongside an miRNA expression vector or a control vector, and luciferase expression is reduced if the miRNA targets the MRE. Site directed mutagenesis or target protector nucleotides can also be used to verify MRE sequence complementarity to the miRNA. Antisense oligonucleotides (molecular sponges) show specificity of a particular miRNA seed sequence for an MRE by complementary binding to the miRNA sequence.[@b11-bmi-suppl.4-2015-025] Viral miRNA deletion mutants are also used to verify the biological function of individual or clusters of miRNAs.

Biomarker and Therapeutic Potential of miRNAs During Viral Infection
====================================================================

The majority of known virally encoded miRNAs are found within DNA viruses that replicate in the nucleus. The first viral miRNAs discovered were found to be expressed by Epstein--Barr virus (EBV).[@b12-bmi-suppl.4-2015-025] Since then, the great majority of miRNAs have been discovered in herpesviruses. A few viral miRNAs have also been reported in other human DNA virus families, including polyomaviruses (described below) and possibly adenoviruses (in very low abundance from virus-associated RNAs). In addition, miRNAs have been reported in DNA viral families that do not infect humans, namely, ascoviruses (Heliothis virescens ascovirus), baculoviruses (Bombyx mori nuclear polyhedrosis virus), and nimaviruses (white spot syndrome virus). Notably, miRNAs from human papillomaviruses (HPVs) have yet to be definitively discovered.

Retroviruses possess a replication stage that involves nuclear DNA as a result of reverse transcription, and miRNAs have indeed been discovered in a few retroviruses, including avian leucosis virus subgroup J, African green monkey simian foamy virus, and bovine leukemia virus.[@b13-bmi-suppl.4-2015-025],[@b14-bmi-suppl.4-2015-025] As will be discussed later, miRNAs have been reported from the human immunodeficiency virus (HIV)-1 transactivation response (TAR) RNA of CD4 T cells,[@b15-bmi-suppl.4-2015-025]--[@b17-bmi-suppl.4-2015-025] although other studies have failed to find biologically relevant viral miRNAs from HIV-1-or human T-lymphotropic virus-infected cells.[@b18-bmi-suppl.4-2015-025]--[@b20-bmi-suppl.4-2015-025]

The existence of miRNAs in cytoplasmic RNA viruses has yet to be detected, and several reasons have been proposed as to why they are unlikely in cytoplasmic viruses. The nuclear location of Drosha and DGCR8, necessary for genesis of pre-miRNAs, is one of the leading explanations for this absence. Interestingly, Rouha et al engineered a nuclear-replicating RNA virus to contain a miRNA-precursor stem-loop sequence element within its RNA genome. They found that a functional miRNA was produced without affecting viral replication,[@b21-bmi-suppl.4-2015-025] implying the possible existence of Drosha-independent miRNA generation pathways within the cytoplasm.

Herpesviruses
-------------

Herpesviruses are large, double-stranded DNA viruses that infect a range of invertebrate and vertebrate animals. Nine human herpesviruses (HHVs) exist, possessing genomes of \~125--230 kb in length. The great majority of miRNAs reported thus far have been found in herpesviruses, and several of the herpesviruses each encode over 20 predicted miRNAs (many of which have not yet been shown to be biologically functional). As DNA viruses that replicate in the nucleus, herpesviruses have access to the nuclear proteins Drosha and DGCR8 that are necessary for the processing of primary miRNAs (pri-miRNAs). Several herpesviruses appear to have autoregulatory miRNAs, including those that maintain latency, while others use miRNAs to modulate cellular responses during infection ([Table 2](#t2-bmi-suppl.4-2015-025){ref-type="table"}).

### Alphaherpesvirinae subfamily members: herpes simplex virus-1 (HSV-1), herpes simplex virus-2, and varicella zoster virus

Members of the *Alphaherpesvirinae* subfamily, herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2), are the causative agents of cold sores and genital herpes, respectively. They establish productive (lytic) infection in epithelial cells and eventually infect sensory neurons, where they become latent and persist for the lifetime of the host.

The process of virion replication takes \~18--20 hours to complete and occurs in three stages corresponding to the expression of immediate early (IE; α), early (E; β), and late (L; γ) genes. During latency, there is little detectable transcription of IE, E, or L genes in infected neurons, even though it is known that they produce high levels of untranslated latency-associated transcripts (LATs). An unstable spliced 6.3 kb transcript and two stable LAT introns of 2 kb and 1.5 kb are spliced from an unstable 8.3 kb primary transcript.[@b22-bmi-suppl.4-2015-025]--[@b25-bmi-suppl.4-2015-025] Although protein products of the LAT gene locus have not been discovered, the site has been associated with the repression of IE gene transcription and the maintenance of latency.[@b26-bmi-suppl.4-2015-025]--[@b28-bmi-suppl.4-2015-025] More recently, miRNAs of both virus and host origin have been connected with maintaining HSV-1 or HSV-2 latency.

According to [miRBase.org](http://miRBase.org),[@b29-bmi-suppl.4-2015-025] 18 virus-derived pre-miRNAs have been identified from HSV-1 that encode 27 mature miRNAs. Many of these have been identified using bioinformatics or sequencing analysis and have yet to be characterized in functional biological assays. The best characterized miRNAs are HSV1-miR-H1 through miR-H6. miR-H1 and miR-H6 are located in the LAT promoter, while miR-H2, miR-H3, miR-H4, and miR-H5 are derived from the primary LAT transcript ([Fig. 1](#f1-bmi-suppl.4-2015-025){ref-type="fig"}).[@b30-bmi-suppl.4-2015-025]

The targets of most HSV-1 miRNAs are still unknown, but those that have been characterized point to a role in preventing viral reactivation from latency through regulation of *ICP0, ICP34.5*, and *ICP4* genes. miR-H2 is derived from the large LAT transcript and is antisense to *ICP0*. Transient-transfection assays showed that miR-H2 is able to downregulate the IE ICP0 protein,[@b31-bmi-suppl.4-2015-025],[@b32-bmi-suppl.4-2015-025] which functions as a transactivator of IE, E, and L genes and, consequently, promotes viral replication. Also derived from the large LAT transcript, miR-H4 (and possibly miR-H3) inhibits the expression of ICP34.5,[@b33-bmi-suppl.4-2015-025] a neurovirulence factor and L gene product that induces transcription. Similarly, miR-H6 can repress the translation of the ICP4 protein,[@b31-bmi-suppl.4-2015-025] an IE protein transactivator that is essential for the maximal transcription of E and L genes. By suppressing the transcription of ICP0, ICP4, and ICP34.5 genes, these LAT-derived or LAT-associated miRNAs may be a component of maintaining latency and suppressing active viral replication.

The earliest studies of HSV-1 miRNAs described their roles in maintaining latency. It is now known that many of these are also present and differentially expressed during productive infection.[@b30-bmi-suppl.4-2015-025],[@b34-bmi-suppl.4-2015-025],[@b35-bmi-suppl.4-2015-025] For example, miR-H1 and miR-H6 are more highly expressed than miR-H2, miR-H3, and miR-H4 during productive infection than latency.[@b30-bmi-suppl.4-2015-025] The opposite is true during latency, implying that miRNA expression plays a role in controlling the ordered expression of viral genes. Flores et al took the analysis of HSV-1 miRNA a step further by examining which of the miRNAs are loaded into the RISC as an indication of miRNA biological function. Surprisingly, only nine HSV-1 miRNAs were found to be associated with the RISC. In addition, the miRNAs were found to associate with the RISC at differing rates,[@b33-bmi-suppl.4-2015-025] suggesting that several may not be functional. A recent study by Belter et al shows that miRNAs in high concentration are able to form secondary structures resembling RNA aptamers,[@b36-bmi-suppl.4-2015-025] molecules whose specific 3D shapes allow them to bind targets with high affinity in the absence of the RISC.

A recent report indicates that host-derived miRNAs may also play a role in promoting HSV-1 latency. Pan et al found that the neuron-expressed miR-138 downregulated the expression of ICP0. A mutant HSV-1 virus lacking an ICP0 mRNA site complementary to miR-138 showed a twofold to fourfold decrease in ICP0 protein in neuronal cells.[@b37-bmi-suppl.4-2015-025] Notably, the expression of ICP0 was unchanged in Vero cells infected with the mutant virus, further emphasizing that cell type is an important factor in determining the biological relevance of both viral and host miRNAs.

HSV-2 is the causative agent of genital herpes. Although viral miRNAs are not necessarily conserved between related viruses, HSV-2 shares \~85% homology with HSV-1 and has several miRNAs located at corresponding locations within its genome. HSV-2 miRNAs often share a high degree of homology with their HSV-1 counterparts when considering the seven-base pair seed regions of the miRNAs.[@b30-bmi-suppl.4-2015-025] HSV-2 miRNAs have also been shown to exert similar regulation upon orthologous HSV-2 genes. For example, both HSV-2 miR-H2 (ie, miR-III) and HSV-1 miR-H2 are able to repress ICP0.[@b32-bmi-suppl.4-2015-025] Similarly, HSV-2 miR-H3 and miR-H4 (ie, miR-I and miR-II, respectively), which are found in high copy number in neurons, are complementary to and lead to the downregulation of ICP34.5.[@b32-bmi-suppl.4-2015-025],[@b38-bmi-suppl.4-2015-025] There are exceptions to this conservation that demonstrate that the relative expression of each miRNA is not necessarily the same between the two viruses and that they may differentially regulate the expression patterns of viral genes. Specifically, miR-H2 is the most highly expressed miRNA during HSV-1 infection, while miR-H3 is most abundant during HSV-2 infection.[@b39-bmi-suppl.4-2015-025] Additionally, not all miRNAs are identical between the two viruses: HSV-2 lacks an ortholog of miR-H1 and the miR-H6 found in HSV-2 uses the 5′ strand of the miRNA duplex, whereas HSV-1 miR-H6 uses the 3′ strand.[@b30-bmi-suppl.4-2015-025],[@b31-bmi-suppl.4-2015-025] Interestingly, the seed sequence of the HSV-2 miR-H6 5′ strand is identical to the seed sequence of the HSV-1 miR-H1, although the targets of either miRNA are currently unknown.[@b30-bmi-suppl.4-2015-025]

HSV-2 encodes a total of 18 virus-derived pre-miRNAs that derive 24 mature miRNAs. HSV-1 miR-H1, miR-H8, miR-H14, miR-H18, miR-H26, and miR-H27 have no known HSV-2 counterparts, while HSV-2 uniquely encodes miR-H9, miR-H10, and miR-H19 through miR-H25.

Varicella zoster virus (VZV; officially HHV-3) is the final member of the *Alphaherpesvirinae* subfamily and causes chickenpox (varicella) during primary infection and shingles (herpes zoster) upon reactivation. The latency program of VZV is different from that of HSV-1 and HSV-2. VZV lacks the *LAT* locus and does not have an RNA transcript analogous to LAT. In addition, it expresses several proteins during latency,[@b40-bmi-suppl.4-2015-025] which is not characteristic of HSV-1 and HSV-2. Deep sequencing of human trigeminal ganglia identified VZV genomic DNA but no VZV-specific miRNAs during latency.[@b41-bmi-suppl.4-2015-025] In support of this result, it was reported in the same study that miRNAs were not able to be recovered from the trigeminal ganglia of rhesus macaques infected with the related simian varicella virus, although they have been discovered in other animal varicelloviruses, bovine herpesvirus 1 and suid herpesvirus 1 (Aujeszky's disease virus/pseudorabies virus).[@b42-bmi-suppl.4-2015-025]--[@b44-bmi-suppl.4-2015-025] It is worth noting, however, that the miRNAs from suid herpesvirus 1 map to the large latency transcript and are complementary to IE transactivators *EP0* and *EP180*,[@b43-bmi-suppl.4-2015-025],[@b44-bmi-suppl.4-2015-025] which are homologs of HSV-1 *ICP0* and *ICP4*.[@b45-bmi-suppl.4-2015-025] It is thus possible that the miRNAs of Suid herpesvirus 1 share conserved function with miRNAs of HSV-1, but not those of VZV. Computational analyses have predicted that VZV does not encode any miRNAs,[@b18-bmi-suppl.4-2015-025] although the possibility of VZV miRNAs during productive infection has yet to be fully examined.

### Gammaherpesvirinae subfamily members: EBV and Kaposi's sarcoma-associated herpesvirus

EBV (HHV-4) and KSHV (HHV-8) are the two herpesviruses within the *Gammaherpesvirinae* subfamily of herpesviruses. Both viruses productively infect and become latent within lymphocytes or lymphoid tissues, and both can induce transformation of infected cells that can lead to malignancies.

EBV causes 90% of the cases of mononucleosis in teenagers or adults. The virus is also associated with Burkitt's lymphoma (BL), Hodgkin's lymphoma, primary effusion lymphoma (PEL), nasopharyngeal carcinoma (NPC), and gastric carcinomas (GaCas).

EBV was the first virus demonstrated to express miRNAs.[@b12-bmi-suppl.4-2015-025] There are two clusters in the EBV genome that encode 25 pre-miRNAs that ultimately produce 44 mature miRNAs. The BamHI fragment H rightward open reading frame 1 (BHRF1) cluster is found within the BHRF1 locus and encodes three miRNAs: miR-BHRF1-1, miR-BHRF1-2, and miR-BHRF1-3. miR-BHRF1-1 is located in the promoter of BHRF1, whereas miR-BHRF1-2 and miR-HBRF1-3 are encoded in the 3′-UTR region of the gene. The second cluster of EBV miRNAs is located within introns of the BamH1-A region rightward transcript (BART) locus. This cluster encodes miR-BART1 through miR-BART22, with the exception of miR-BART2, which is found downstream of the BART locus between *BILF1* and *BALF5* genes.[@b46-bmi-suppl.4-2015-025],[@b47-bmi-suppl.4-2015-025]

EBV establishes and maintains persistent infection through a series of transcription programs characterized by regulated viral gene expression,[@b48-bmi-suppl.4-2015-025] and the expression of certain miRNAs correlates with the latency program of infected cells. The first transcription program, known as Latency 3 or the growth transcription program, occurs when EBV infects a naïve B cell. This causes the cell to differentiate into a lymphoblast and proliferate. As with normally activated B lymphoblasts, the cell migrates to the lymph node germinal center follicle and continues to proliferate. It is at this point that the cell switches to the Latency 2 transcription program, also known as the default transcription program, which induces cell differentiation that causes the cell to leave as a resting memory B cell. In the periphery, the Latency 0 program initiates and protein translation ceases, except during the Latency 1 program, when the cell divides due to the expression of EBNA1. The process of productive viral replication and shedding into saliva is provoked by memory cells that return to the tonsil and undergo differentiation into antibody-producing plasma cells.[@b48-bmi-suppl.4-2015-025]

The BHRF1 miRNAs are highly expressed during the Latency 3 transcription program of infected BL and in lymphoblastoid cell lines (LCLs), which are generated through EBV infection of resting B cells.[@b49-bmi-suppl.4-2015-025] Studies that created mutant viruses by introducing mutations into the BHRF1 miRNAs showed that these miRNAs are involved in contributing to B cell transformation by promoting cell-cycle progression and inhibiting apoptosis.[@b50-bmi-suppl.4-2015-025],[@b51-bmi-suppl.4-2015-025] In stark contrast, BHRF1 miRNAs were not detectable in NPC, PEL, or BL cell lines in Latency 1 or 2 transcription programs, whereas BART miRNAs were expressed to high levels.[@b49-bmi-suppl.4-2015-025] In addition, NPC and GaCa epithelial tumors exhibited 13- and 8-fold higher expression, respectively, of BART miRNAs compared to LCLs.[@b52-bmi-suppl.4-2015-025] Taken together, this suggests that BART miRNAs appear to be preferentially expressed in epithelial cells (such as NPCs), while they are moderately expressed in B cells and dispensable for in vitro EBV-induced transformation.[@b53-bmi-suppl.4-2015-025]

Several viral and host mRNA targets of EBV miRNAs have been identified. miR-BART2 is complementary to *BALF5* and downregulates the expression of this viral DNA polymerase,[@b12-bmi-suppl.4-2015-025],[@b54-bmi-suppl.4-2015-025] and miR-BART10 targets the 3′-UTR of *BHRF1* to inhibit apoptosis.[@b55-bmi-suppl.4-2015-025] Several EBV miRNAs (miR-BART3, miR-BART5, miR-BART16, miR-BART17, miR-BART19, and miR-BART20) have been reported to downregulate latent membrane protein 1 (LMP1), an EBV integral membrane protein that functions as an oncogene by promoting cell survival and preventing apoptosis.[@b55-bmi-suppl.4-2015-025]--[@b57-bmi-suppl.4-2015-025] Although it is counterintuitive that EBV miRNAs would negatively regulate LMP1, high levels of LMP1 can actually promote apoptosis,[@b58-bmi-suppl.4-2015-025] and so tight control of the gene is necessary. It is also of interest to note that *BZLF1* and *BRLF1*, two EBV genes associated with the switch from latency to lytic infection, are not targeted in BL cell lines by these EBV miRNAs.[@b55-bmi-suppl.4-2015-025] This indicates that these miRNAs are not directly responsible for regulating the latent-lytic switch, unlike HSV-1 and HSV-2 miRNAs.

Also, EBV miRNAs can target host mRNAs to prevent apoptosis. Gene ontology analysis of the host mRNA targets of the 12 most abundant EBV miRNAs indicated that 132 apoptosis-associated host genes may be targeted by EBV miRNAs.[@b55-bmi-suppl.4-2015-025] Notably, the p53 upregulated mediator of apoptosis (PUMA), a pro-apoptotic gene induced by p53, has been shown to be targeted by miR-BART5 and miR-BART19.[@b55-bmi-suppl.4-2015-025],[@b59-bmi-suppl.4-2015-025] Also related to promoting apoptosis, the BCL2 family member *BCL2L11* (BIM) is targeted by miR-BART4 and miR-BART15,[@b60-bmi-suppl.4-2015-025] and possibly several miRNAs together,[@b61-bmi-suppl.4-2015-025] to orchestrate the downregulation of this target. EBV-infected GaCa cell lines exhibited reduced apoptosis due to the interaction of miR-BART4 with *BID*, another Bcl-2 family member involved in regulating apoptosis.[@b62-bmi-suppl.4-2015-025] Again, differential expression of these miRNAs may occur depending upon the type of cell (B cell versus epithelial cell) or latency program.[@b47-bmi-suppl.4-2015-025]

EBV miRNAs have also been implicated in evasion of NK cells through miR-BART2-mediated downregulation of MHC Class I Polypeptide-Related Sequence B (MICB), a stress-induced NK cell ligand, in epithelial cell lines.[@b55-bmi-suppl.4-2015-025],[@b63-bmi-suppl.4-2015-025] In addition, the T cell-attracting chemokine CXCL11, produced by B cells during EBV infection, is downregulated by EBV miR-BHRF1-3.[@b12-bmi-suppl.4-2015-025],[@b64-bmi-suppl.4-2015-025] EBV miR-BART18 decreases the histone acetylase cyclic AMP-responsive element-binding protein (CBP),[@b65-bmi-suppl.4-2015-025] which along with p300 associates with IRF3 and IRF7 to induce the transcription of Type 1 interferon (IFN) genes. Blocking miR-BART18 in Akata A.15 cells, an EBV+BL cell line, led to increased Type 1 IFN signaling, as measured in terms of *ISG*-*15* expression using Northern blot.[@b65-bmi-suppl.4-2015-025] As Type 1 IFN is important in inducing an antiviral state and activating NK and T cells, miRNA-mediated downregulation of the expression of this cytokine would be expected to greatly benefit the virus. Taken together, this work shows that in addition to preventing apoptosis of infected cells, viral miRNAs may also function to prevent host immune effects without the use of immunogenic viral proteins. All herpesviruses still contain a large cohort of protein-encoding genes that interfere with host immune responses, which raises the question of the relative *in vivo* significance of viral miRNAs versus proteins. Infection of mouse models with homologous miRNA-deficient herpesvirus strains will likely provide important context within an *in vivo* system.

The other human gammaherpesvirus is Kaposi's sarcoma-associated herpesvirus (KSHV) (HHV-8). The greatest risk of infection with KSHV is for immunocompromised individuals, who more frequently develop Kaposi's sarcoma. Like EBV, KSHV infection is also associated with PEL and multicentric Castleman disease.[@b66-bmi-suppl.4-2015-025]

According to [miRBase.org](http://miRBase.org),[@b29-bmi-suppl.4-2015-025] 13 pre-miRNAs and 25 miRNAs are found within the KSHV genome. The miRNAs are all located as a cluster within the KSHV latency-associated region (KLAR), which encodes four genes expressed during latency and lytic infection: latency-associated nuclear antigen (LANA), v-Cyclin, v-FLIP, and Kaposin (K12). All the miRNAs map to the K12 locus: miR-K12-1 through miR-K12-9 and miR-K12-11 are encoded within the K12 intron, while miR-K12-10 and miR-K12-12 map to a K12 open reading frame and the 3′-UTR, respectively ([Fig. 2](#f2-bmi-suppl.4-2015-025){ref-type="fig"}).[@b18-bmi-suppl.4-2015-025],[@b67-bmi-suppl.4-2015-025],[@b68-bmi-suppl.4-2015-025] Although the relative expression levels can vary in different cell types, the 10 miRNAs encoded on the K12 intron are generally expressed as a group in latently infected cells.[@b9-bmi-suppl.4-2015-025],[@b69-bmi-suppl.4-2015-025],[@b70-bmi-suppl.4-2015-025] In contrast, miR-K12-10 and miR-K12-12 are expressed alongside the K12 gene during lytic infection.[@b71-bmi-suppl.4-2015-025]

The cluster of KSHV miRNAs is expressed alongside the KLAR genes during latency, and similar to HSV-1 and HSV-2 miRNAs, it has been shown to play a role in preventing reactivation to the lytic cycle. The expression of the KSHV replication and transcription activator (RTA), the master regulator of the latent-lytic switch, is negatively regulated by miR-K12-9 and miR-K12-7.[@b72-bmi-suppl.4-2015-025],[@b73-bmi-suppl.4-2015-025] Similarly, miR-K12-3 and miR-K12-11 target cellular activators of RTA.[@b74-bmi-suppl.4-2015-025] Inhibiting or eliminating these KSHV miRNAs (or a cluster including these miRNAs) induced elevated lytic gene expression and spontaneous lytic reactivation in fibroblasts, endothelial cells, and PEL cells.[@b72-bmi-suppl.4-2015-025]--[@b75-bmi-suppl.4-2015-025] This further emphasizes that several KSHV miRNAs are involved in the maintenance of latency in both lymphoid and non-lymphoid cells. It is also interesting to note that host-encoded miR-498 and miR-320d have also been shown to target RTA in a PEL cell line,[@b76-bmi-suppl.4-2015-025] and 5 of the 99 cellular miRNAs induced by ectopic expression of HIV *nef* have putative binding sites in the 3′-UTR of the RTA gene.[@b77-bmi-suppl.4-2015-025]

Recent work by McClure et al and Bai et al mapped the 3′-UTRs of KSHV genes and discovered that these regions are important in the negative regulation of KSHV genes.[@b78-bmi-suppl.4-2015-025],[@b79-bmi-suppl.4-2015-025] A total of 28 potential KSHV gene targets of known KSHV miRNAs were identified that correspond to all stages of viral replication,[@b79-bmi-suppl.4-2015-025] indicating that many miRNA targets have yet to be investigated.

In addition to viral transcripts, KSHV miRNAs target many host mRNAs. Notably, KSHV miRNAs are thought to target \>1000 putative host genes,[@b9-bmi-suppl.4-2015-025],[@b70-bmi-suppl.4-2015-025] although not necessarily directly.[@b80-bmi-suppl.4-2015-025] Several classes of cellular genes consistently targeted include apoptosis, angiogenesis, cellular metabolism, lymphocyte activation, and immune modulation genes.[@b9-bmi-suppl.4-2015-025],[@b80-bmi-suppl.4-2015-025],[@b81-bmi-suppl.4-2015-025] For example, several KSHV miRNAs target cellular thrombospondin 1, which is thought to negatively regulate angiogenesis and proliferation.[@b81-bmi-suppl.4-2015-025] KSHV miR-K12-K1 binds the 3′-UTR of *CDKN1A* (p21) to inhibit p53-induced cell-cycle arrest in PEL B cells.[@b82-bmi-suppl.4-2015-025] Similar to EBV, *MICB* is also targeted by miR-K12-K7, a KSHV miRNA.[@b63-bmi-suppl.4-2015-025] Haecker et al used Ago HITS-CLIP to identify a collection of cellular pathways targeted by KSHV miRNAs. Identified genes included 42 involved in apoptosis, 11 in cellular metabolism (glycolysis), 13 in lymphocyte activation (in BCBL-1 cells), and 21 in mitosis (in BC-3 cells).[@b9-bmi-suppl.4-2015-025] This emphasizes that this complex virus is capable of affecting multiple host signaling pathways through the effects of numerous viral miRNAs.

As a herpesvirus, KSHV encodes several viral orthologs of host genes, including *IL6*, *CFLAR* (FLIP), *CCND*, and *IRF3*. Similarly, the virus also encodes orthologs of host miRNAs. KSHV expresses miR-K12-11, an ortholog of the human miR-155, during latent infection.[@b83-bmi-suppl.4-2015-025] Host miR-155 is involved in the clonal expansion of lymphocytes following antigenic stimulation,[@b84-bmi-suppl.4-2015-025] and miR-155 transgenic mice have been shown to develop B cell lymphomas,[@b85-bmi-suppl.4-2015-025] lending support to the hypothesis that miR-K12-11 may assist in the induction of oncogenic processes within cells. Notably, although the related gammaherpesvirus EBV does not encode its own ortholog of miR-155, this cellular miRNA is the most abundant miRNA (of cell or virus origin) induced by EBV infection of LCLs.[@b86-bmi-suppl.4-2015-025] KSHV miR-K12-10a and miR-K12-3 (including the SNP-containing miR-K12-3+1) also act as viral orthologs of cellular miR-142-3p and miR-23, respectively.[@b70-bmi-suppl.4-2015-025],[@b87-bmi-suppl.4-2015-025] The viral and cellular miRNAs can show mutually exclusive expression in different cell types; however, miR-23 is highly detected in endothelial cells, while miR-K12-3 is expressed in PEL cell lines.[@b87-bmi-suppl.4-2015-025] Similarly, cellular miR-155 is highly expressed in infected endothelial cells, while miR-K12-11 is expressed in PEL cell lines.[@b88-bmi-suppl.4-2015-025]

In addition to encoding homologs of cellular miRNAs and its own miRNAs that target host genes, KSHV also expresses proteins that induce several infection-promoting cellular miRNAs. For example, knocking down cellular miR-21 and miR-31 prevented KSHV K15M-mediated motility of PEL cells,[@b89-bmi-suppl.4-2015-025] and cellular miR-132 regulates interferon-stimulated genes in KSHV-infected lymphatic endothelial cells.[@b90-bmi-suppl.4-2015-025] It is not surprising that several herpesviruses use miRNAs to interfere with Type 1 IFN signaling; miR-K12--12 also appears to target CBP, which is involved in the activation of Type 1 IFN genes.[@b65-bmi-suppl.4-2015-025]

### Betaherpesvirinae subfamily members: human cytomegalovirus, HHV-6A, HHV-6B, and HHV-7

Human cytomegalovirus (HCMV; officially HHV-5), HHV-6A, HHV-6B, and HHV7 establish latency in leukocytes and are characterized by slower replication than the other herpesviruses. Healthy individuals generally do not display symptoms when infected with HCMV, although 10--20% of infectious mononucleosis cases are attributed to the virus. The virus can reactivate and cause life-threatening disease in immunocompromised individuals, and HCMV is the most prevalent congenital infection in industrialized countries.

According to [miRBase.org](http://miRBase.org),[@b29-bmi-suppl.4-2015-025] 15 pre-miRNAs encode 26 mature HCMV miRNAs. Unlike KSHV or EBV, the HCMV miRNAs are scattered throughout the viral genome. They can be found on both strands, present in 3′-UTRs or within intergenic regions.[@b91-bmi-suppl.4-2015-025]

HCMV miRNAs target both viral and host genes. Most HCMV miRNAs correlate with the expression of lytic genes.[@b92-bmi-suppl.4-2015-025],[@b93-bmi-suppl.4-2015-025] miR-UL112-1 targets several HCMV genes, including IE1, IE72, UL112/113, UL114, and UL120/121.[@b94-bmi-suppl.4-2015-025]--[@b96-bmi-suppl.4-2015-025] The expression of UL138, a viral protein that contributes to latency,[@b97-bmi-suppl.4-2015-025] is decreased 46% in miR-UL36-transfected HEK293 cells,[@b98-bmi-suppl.4-2015-025] suggesting that this miRNA may be involved in maintaining productive infection. However, no HCMV miRNA has been found to be essential for replication.

Although the majority of its miRNAs have been characterized during lytic infection, HCMV may also encode a subset of miRNAs that self-regulate to maintain a latent state. As mentioned above, miR-112-1 has been shown to downregulate IE72, an abundant HCMV transactivator necessary for induction of E and L gene expression.[@b95-bmi-suppl.4-2015-025] The HCMV IE1 and IE2 transactivators are central to reactivation from latency,[@b99-bmi-suppl.4-2015-025] and HCMV miR-112-1 binds to the 3′-UTR of IE1 and reduces reporter expression in transient-transfection assays of HEK293T cells.[@b96-bmi-suppl.4-2015-025] In support of this, miR-US33 transfection of human embryo lung fibroblast cells reduced infectious viral titers and IE1/IE2 proteins at a multiplicity of infection of 0.01 (although not 0.1, 1, or 5).[@b93-bmi-suppl.4-2015-025] Thus, although few HCMV miRNAs are found to be expressed during latency, several putative miRNAs may have a significant effect upon the suppression of required IE genes.

In addition to targeting viral genes, HCMV also encodes miRNAs that target cellular genes. For example, miR-US25-1 and miR-US25-2 target several cellular targets, many of which are associated with cell-cycle control, and infection with an miR-US25-1 knockout virus resulted in increased cyclin E2 expression in human primary fibroblast cells.[@b100-bmi-suppl.4-2015-025] Like other herpesvirus miRNAs, HCMV also encodes miRNAs that target cellular genes in an effort to evade host immune responses. Notably, HCMV miR-UL112 was the first miRNA shown to inhibit expression of MICB. It also acts in concert with the HCMV-encoded UL16 protein to inhibit expression of MICB when UL16 protein levels are reduced.[@b101-bmi-suppl.4-2015-025] CCL5, a chemokine that attracts T cells, is downregulated in human foreskin fibroblasts by HCMV miR-UL148D,[@b102-bmi-suppl.4-2015-025] while MHC Class I peptide loading is inhibited by the miR-US4-1-mediated downregulation of endoplasmic reticulum (ER) aminopeptidase 1 (ERAP1).[@b103-bmi-suppl.4-2015-025] Taken together, HCMV encodes several miRNAs that function to regulate host responses.

Whereas HHV-6A is an orphan virus, HHV-6B and HHV-7 cause roseola infantum and are associated with febrile seizures of children below two years of age. Deep sequencing has identified four miRNAs, termed hhv6b-miR-Ro6-1 through miR-Ro6-4, encoded within the left and right direct repeat regions of HHV-6B.[@b104-bmi-suppl.4-2015-025] Hhv6b-miR-Ro6-3, miR-Ro6-2, and miR-Ro6-1 are antisense to the predicted B1, B2, and B3 open reading frames (ORFs), respectively, that are thought to encode IE genes.[@b105-bmi-suppl.4-2015-025] Future studies will determine if these HHV-6 miRNAs are involved in regulating early lytic infection or maintaining latency. Thus far, no viral miRNAs have been identified for HHV-7.

### Biomarker and therapeutic potential with respect to herpesvirus miRNAs

Herpesviruses encode proteins that subvert host immune responses, and it is clear that the viruses also encode several miRNAs that interfere with innate and adaptive antiviral mechanisms. Type 1 IFN signaling activates a variety of cellular antiviral pathways and is a potent inducer of NK cell activation and cytotoxicity.[@b106-bmi-suppl.4-2015-025] Not surprisingly, HCMV, EBV, and KSHV encode miRNAs that target Type 1 IFN signaling,[@b65-bmi-suppl.4-2015-025] and these viruses also encode miRNAs that downregulate MICB.[@b55-bmi-suppl.4-2015-025],[@b63-bmi-suppl.4-2015-025],[@b101-bmi-suppl.4-2015-025] Blocking miR-BART18 in an EBV+ BL cell line resulted in increased Type 1 IFN signaling,[@b65-bmi-suppl.4-2015-025] highlighting that efforts to inhibit herpesvirus miRNAs could be fruitful in reestablishing IFN-induced antiviral pathways. Likewise, inhibition of viral miRNAs may be useful to reverse IFN refractoriness of EBV+ or KSHV+ tumor cells[@b65-bmi-suppl.4-2015-025] or increase the efficacy of interferon therapy for herpesvirus conditions, such as HSV epithelial keratitis.[@b107-bmi-suppl.4-2015-025] Conversely, these herpesvirus miRNAs could assist in the regulation of aberrant Type 1 IFN responses in systemic lupus erythematosus and other diseases.[@b108-bmi-suppl.4-2015-025]

Adaptive immune responses are also circumvented through herpesvirus miRNAs, either directly or indirectly. Inhibition of Type 1 IFN signaling through miRNAs mentioned above can negatively regulate antigen-presenting cell (APC) and CD8 T cell responses.[@b109-bmi-suppl.4-2015-025],[@b110-bmi-suppl.4-2015-025] In addition, T cell-attracting chemokines CXCL11 and CCL5 are targeted by EBV and HCMV miRNAs, respectively,[@b12-bmi-suppl.4-2015-025],[@b64-bmi-suppl.4-2015-025],[@b102-bmi-suppl.4-2015-025] and HCMV miR-US4-1 downregulates ERAP1 to inhibit MHC Class I peptide loading in the ER.[@b103-bmi-suppl.4-2015-025] Correspondingly, inhibition of herpesvirus miRNAs during infection would be expected to modulate APC and T cell responses.

Herpesvirus miRNAs have huge potential as biomarkers of diagnosis and disease progression. As an example, HCMV is the most common infection of patients after organ transplantation and can drastically affect morbidity, mortality, and organ rejection. Diagnostic results assist in monitoring of infection following transplantation and guide decisions to give preemptive therapy.[@b111-bmi-suppl.4-2015-025] The current standards to test for acute infection include serology for IgM/IgG titers, an antigenemia assay to test for HCMV pp65 antigen, and quantitative nucleic acid testing (QNAT) using PCR. However, false-positive serology results can occur in patients with EBV or HHV-6 infections, and IgM antibodies take weeks to appear. This underscores the limitations of traditional serology to quickly assess new infection. Moreover, the pp65 antigenemia assay cannot be used in patients with neutropenia, and QNAT is extremely sensitive and faster than culture but does not differentiate between shedding of virus in the absence of active disease.[@b111-bmi-suppl.4-2015-025] Certain HMCV miRNAs are expressed at different stages of viral replication and could therefore be used to further monitor primary infection or reactivation from latency. Samples could be easily obtained from biopsies, whole blood or plasma, known areas of shedding such as saliva, or other fluids such as cerebrospinal fluid. In support of using herpesvirus miRNAs as biomarkers, Kawano et al found that certain EBV miRNAs were elevated in plasma of patients with chronic active EBV infection compared to control patients or patients with infectious mononucleosis.[@b112-bmi-suppl.4-2015-025] A recent study by Zhang et al found that EBV miR-BART7 and miR-BART13 levels in plasma specimens produce a 90% predictive value for NPC. In addition, both miRNAs were downregulated following radiotherapy.[@b113-bmi-suppl.4-2015-025]

Exosomes, which are lipid microvesicles released from cells, are thought to provide extra stability to their encapsulated miRNAs. Exosome miRNA can be separated from free miRNAs, virion-associated miRNAs, or genomic nucleic acid.[@b114-bmi-suppl.4-2015-025] miRNAs have been detected within exosomes in plasma from human patients with KSHV and from EBV+ LCL and NPC cell lines.[@b69-bmi-suppl.4-2015-025],[@b114-bmi-suppl.4-2015-025]--[@b116-bmi-suppl.4-2015-025] Exosome-associated miRNAs in plasma could provide more stable samples for analysis, leading to better diagnostics to monitor active infection or herpesvirus-associated malignancies.

Although some herpesviruses exhibit conservation in their miRNA seed regions, diagnostic miRNA microarrays could provide a means to differentiate between herpesvirus infections that cause similar conditions, such as roseola infantum caused by HHV-6B or HHV-7. The plausibility of this idea is supported by a study by Marshall et al that showed that the majority of KSHV-encoded miRNAs were highly conserved within clinical isolates.[@b69-bmi-suppl.4-2015-025] Because reactivation from latency is a critical step in the replication of herpesviruses, comparison of lytic versus latent miRNAs may also be useful in diagnosis, monitoring, and treatment. Although excellent work has been done to elucidate the biological functions of the miRNAs present during herpesvirus infection, additional serum profiling studies from infected individuals need to be performed in order to have a more thorough understanding of which viral and cellular miRNAs are present during the different stages of herpesvirus infection.

Polyomaviruses
--------------

Another family of double-stranded DNA viruses that replicate in the nucleus is the *Polyomaviridae*. The family is divided into three genera, two of which infect mammalian hosts while the third infects avian hosts. A curiosity of the polyomaviruses lies in the fact that humans exhibit subclinical persistent infection at very high rates in the population, with primary infection occurring at a young age. It is unclear whether or not there is a true latent stage, but asymptomatic individuals routinely shed polyomavirus particles in their blood and urine.

Infections of humans with polyomaviruses can result in serious diseases, although it is usually quite rare. For example, infection with Merkel cell polyomavirus (MCPyV) can lead to Merkel cell carcinoma[@b117-bmi-suppl.4-2015-025] and BK polyomavirus (BKPyV) can cause polyomavirus allograft nephritis, polyomavirus hemorrhagic cystitis, and bladder cancer in some cases.[@b118-bmi-suppl.4-2015-025]--[@b125-bmi-suppl.4-2015-025] Additionally, JC polyomavirus (JCPyV) can cause progressive multifocal leukoencephalopathy (PML) and has been associated with cases of colorectal cancer,[@b126-bmi-suppl.4-2015-025],[@b127-bmi-suppl.4-2015-025] while trichodysplasia spinulosa-associated polyomavirus can cause trichodysplasia.[@b128-bmi-suppl.4-2015-025]

As nuclear DNA viruses, polyomaviruses are good candidates to encode miRNAs. Unlike the herpesviruses that each encodes a handful of miRNAs, most or all polyomaviruses encode a single pre-miRNA within the large T antigen (LTAg) gene ([Table 3](#t3-bmi-suppl.4-2015-025){ref-type="table"}). Although the exact location of the pre-miRNA varies, it is always oriented in the opposite direction of the LTAg and is transcribed as part of late transcription events. Two mature miRNAs are produced from the pre-miRNA that downregulate the expression of the LTAg, which is necessary for the early/middle phase of the infection cycle. Therefore, the main role of the polyomavirus miRNAs appears to be in helping the transition from the early to late phase of the infection cycle.

Cellular targets of polyomavirus miRNAs have also been identified and appear to target immune responses. Both JCPyV and BKPyV miRNAs bind to the 3′-UTR and reduce translation of UL16-binding protein 3 (*ULBP3*) mRNA, a stress-induced ligand of NK cells, in an effort to evade an NK response against the virus.[@b129-bmi-suppl.4-2015-025],[@b130-bmi-suppl.4-2015-025] Cytotoxic T cell responses against SV40, specifically cell lysis and IFN-γ production, are reduced indirectly through viral miRNA-induced downregulation of LTAg and small T antigen.[@b131-bmi-suppl.4-2015-025] Other host targets have been predicted in SV40 and MCPyV, but are yet to be shown experimentally.[@b132-bmi-suppl.4-2015-025],[@b133-bmi-suppl.4-2015-025]

The 5′ and 3′ miRNAs encoded by polyomaviruses appear to have potential as biomarkers of infection and are detectable in plasma, urine, brain tissue, colon tissue, and feces.[@b134-bmi-suppl.4-2015-025]--[@b136-bmi-suppl.4-2015-025] JCPyV miRNA was isolated from both plasma and urine in healthy asymptomatic individuals using qRT-PCR, which was more sensitive in detecting the presence of the virus than traditional serological methods.[@b136-bmi-suppl.4-2015-025] JCPyV miRNA has been found in postmortem brain tissues of PML patients,[@b134-bmi-suppl.4-2015-025] and miR-J1-5p was also detectable in colon tissue and feces of healthy subjects.[@b135-bmi-suppl.4-2015-025] Interestingly, miRNA expression was lower in diseased versus normal adjacent tissue and inversely correlated with expression of LTAg, possibly supporting its role in downregulating expression of the protein.[@b135-bmi-suppl.4-2015-025] Currently, serology for JCV proteins is most commonly used to indicate infection, but together with the apparent stability of the miRNA,[@b134-bmi-suppl.4-2015-025] the ease in obtaining polyomavirus miRNAs from patient samples indicates that they may be powerful biomarkers for detecting asymptomatic forms of polyomavirus infections. On the other hand, using host-encoded miRNAs that are induced by PyV infection as potential biomarkers may not be as fruitful: in a miRNA profiling study, Lagatie et al found that there was no significant difference in host-encoded miRNAs between individuals with or without JCPyV.[@b137-bmi-suppl.4-2015-025]

Using polyomavirus miRNAs or their respective antagomirs (complementary oligonucleotides used to silence miRNAs) as therapeutics will most likely be difficult. A major problem lies in the fact that most individuals are infected asymptomatically by PyVs and never develop serious health consequences. Later, when the virus is assumed to be in a latent form of infection, the miRNA is not being expressed and thus there is no target to antagonize. In cases where tumorigenesis has occurred and a proviral form exists, the virus is likely to be expressing only E genes,[@b138-bmi-suppl.4-2015-025] which does not include the miRNA. Since tumorigenic activity is believed to largely come from the action of LTAg,[@b139-bmi-suppl.4-2015-025] it is interesting to speculate that the PyV miRNA could serve as a therapeutic in malignant cells to theoretically reduce the amount of LTAg expressed. However, this is also likely to induce the lytic cycle, which may have its own unintended consequences.

Hepatitis B virus
-----------------

The hepatitis B virus (HBV) is a small, enveloped DNA virus belonging to the *Hepadnaviridae* family. The primary cellular target of infection by HBV is human hepatocytes. It is estimated that as many as 400 million people may be chronically infected worldwide[@b140-bmi-suppl.4-2015-025],[@b141-bmi-suppl.4-2015-025] with up to 1 million annual deaths, as a result. Not only can chronic HBV infection lead to hepatitis or cirrhosis but also is the cause of up to 80% of the cases of hepatocellular carcinoma (HCC), the fifth most commonly diagnosed cancer and the second most common cause of cancer death in the world.[@b142-bmi-suppl.4-2015-025]

As a DNA virus that enters the nucleus, HBV is a good candidate to encode miRNAs. Nevertheless, no HBV miRNAs have been verified experimentally, and only one has been identified through computational methods.[@b143-bmi-suppl.4-2015-025] On the other hand, there are a large number of host-encoded miRNAs described that interact with HBV and are differentially expressed during the course of infection ([Table 4](#t4-bmi-suppl.4-2015-025){ref-type="table"}). Additionally, miRNAs have been identified that are specifically involved in the progression of HBV-related diseases.[@b144-bmi-suppl.4-2015-025] Thus, cellular miRNAs, rather than viral miRNAs, may have the potential to become powerful biomarkers of HBV pathology.

The most studied miRNA involved in the course of HBV infection is perhaps miR-122. It represents 50--70% of the miRNAs found in normal liver cells[@b145-bmi-suppl.4-2015-025]--[@b147-bmi-suppl.4-2015-025] and plays a role in maintaining homeostasis, as well as regulating metabolic pathways involving lipid and cholesterol metabolism.[@b148-bmi-suppl.4-2015-025],[@b149-bmi-suppl.4-2015-025] miR-122 has been shown to downregulate cyclin G1 and heme oxygenase 1 (HMOX1), resulting in inhibition of HBV replication.[@b150-bmi-suppl.4-2015-025]--[@b152-bmi-suppl.4-2015-025] Additionally, Chen et al found that miR-122 has viral mRNA target sequences located in the HBV coding region of the reverse transcriptase and the 3′-UTR of the HBcAg core protein.[@b153-bmi-suppl.4-2015-025] The virus counters with production of X protein, which binds peroxisome proliferator-activated receptor gamma to inhibit the transcription of miR-122.[@b154-bmi-suppl.4-2015-025] In addition, all four HBV mRNAs have complementary sites for miR-122 that act as sponges to sequester endogenous copies of the miRNA.[@b155-bmi-suppl.4-2015-025]

Not surprisingly, miR-122 is downregulated in a number of HBV-associated hepatic cancers.[@b156-bmi-suppl.4-2015-025] Fan et al showed that miR-122 negatively regulates tumor-promoting N-myc downstream-regulated gene 3, which is upregulated in HCC+ patient liver samples compared to normal adjacent tissue.[@b157-bmi-suppl.4-2015-025] The biological importance of miR-122 was further emphasized when the malignant phenotype of an HBV-related HCC cell line could be reversed by transient transfection of miR-122 into the cells.[@b157-bmi-suppl.4-2015-025] Inhibition of miR-122 also leads to the increased expression of pituitary tumor transforming gene binding factor, resulting in liver cancer cell proliferation, invasion, and tumor growth.[@b158-bmi-suppl.4-2015-025]

Other cellular miRNAs are targeted in a similar manner by HBV. Two well-known tumor suppressor miRNAs, miR-15a and miR-16-1, are found in multiple human cancers and are decreased in HBV-infected cells by HBV X protein.[@b159-bmi-suppl.4-2015-025]--[@b161-bmi-suppl.4-2015-025] As occurs with miR-122, HBV mRNAs have a site complementary to miR-15a and miR-16-1 and act as sponges to sequester the miRNAs. As a result, the oncogene Bcl-2, a regulatory target of miR-15a/16-1, was increased significantly in HBV-transfected cells.[@b162-bmi-suppl.4-2015-025] Viral targeting of these miRNAs, specifically miR-15a, likely evolved in response to the ability of the host miRNA to target HBp and HBx transcripts to suppress HBV infection.[@b159-bmi-suppl.4-2015-025]

Several other cellular miRNAs are induced by infection, although not all result in a benefit to the host. HBsAg expression and HBV proliferation are directly suppressed by miR-199a-3p and miR-210,[@b163-bmi-suppl.4-2015-025] and miR-125a-5p downregulates the expression of HBsAg.[@b164-bmi-suppl.4-2015-025] On the other hand, Zhang et al showed that miR-1 indirectly enhances HBV replication by targeting histone deacetylase 4 and E2F transcription factor 5, the activation of which arrests the cell cycle and reverses the cancer phenotype.[@b165-bmi-suppl.4-2015-025] In support of this, it has been found that miR-1 is epigenetically regulated and found in lower levels in HCC cells.[@b166-bmi-suppl.4-2015-025] Paradoxically, the HBV HBx protein promotes the expression of cellular miR-148a, which enhances tumorigenesis and promotes cell proliferation, cell migration, and anchorage-independent growth of HepG2 and Hep3B cells.[@b167-bmi-suppl.4-2015-025],[@b168-bmi-suppl.4-2015-025] Further research is needed to discern the relationship between tumorigenic and antitumorigenic miRNAs during HBV infection.

### Traditional detection methods and notable miRNA biomarkers of HBV infection

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are the most commonly used biomarkers to assess liver damage,[@b169-bmi-suppl.4-2015-025] although levels can be altered through conditions unrelated to the liver.[@b170-bmi-suppl.4-2015-025],[@b171-bmi-suppl.4-2015-025] A more definitive diagnosis can be obtained by liver biopsy, but biopsy is costly, inconvenient, and may not be accessible to all individuals.[@b172-bmi-suppl.4-2015-025] Furthermore, complications such as pain, mental and physical anguish, bleeding, and even death are possible.[@b172-bmi-suppl.4-2015-025]--[@b174-bmi-suppl.4-2015-025] Another problem with liver biopsy lies in the sampling nature of the biopsy itself. Typically, liver samples taken at biopsy represent 1/50,000th of the total liver, which could result in random sampling error.[@b172-bmi-suppl.4-2015-025] While ultrasound is a tempting noninvasive alternative and good for assessing late stage liver damage, it is not very useful in assessing earlier stages of disease.[@b175-bmi-suppl.4-2015-025]

For specifically identifying HBV as a causative agent of liver damage, current serological methods consist of antibody tests for HBsAg and HBeAg antigens. PCR assays may also be used for direct determination of HBV genomic DNA in serum. For identification of HBV in tissues, detection of HBsAg and HBcAg by immunohistochemical staining or HBV DNA by Southern hybridization, in situ hybridization, or PCR is performed.[@b176-bmi-suppl.4-2015-025]

Considering the above challenges, miRNAs have emerged as an alternative biomarker method with the possibility of monitoring the progression of disease in individuals. Multiple studies have already shown that noninvasive testing for miRNAs has the potential to be used as biomarkers of HBV infection and HBV-positive HCC.[@b177-bmi-suppl.4-2015-025],[@b178-bmi-suppl.4-2015-025] A number of specific, differentially expressed host miRNAs have been identified in the last decade; a partial list is shown in [Table 5](#t5-bmi-suppl.4-2015-025){ref-type="table"}.

One of the most widely used miRNA biomarkers for HBV is miR-122, not surprising due to it being one of the most thoroughly studied miRNAs in HBV infection and liver disease. Waidmann et al found that the serum levels of miR-122 were effective as a biomarker in HBV-infected patients as they discriminated infected from healthy subjects, discriminated inactive carrier patients with high or low levels of HBsAg, and correlated with the levels of ALT, HBV genomic DNA, and HBsAg.[@b179-bmi-suppl.4-2015-025] It has also been shown that both miR-122 and miR-18a are released in the blood and could be used for HBV-related HCC screening.[@b160-bmi-suppl.4-2015-025],[@b179-bmi-suppl.4-2015-025],[@b180-bmi-suppl.4-2015-025] An miRNA profiling study on HBV and hepatitis C virus (HCV) found that miR-122 was significantly upregulated in serum of patients with both viruses, whereas elevated miR-22, miR-99, and miR-125b levels were more characteristic of chronic HBV infection and may be useful in discriminating between infection with the two viruses.[@b181-bmi-suppl.4-2015-025]

Other panels of miRNAs have also been found to be differentially expressed between healthy and chronic HBV patients. Zhang et al identified 34 miRNAs dysregulated in chronic hepatitis B patients, with miR-122, miR-572, miR-575, and miR-638 upregulated and miR-744 downregulated significantly.[@b182-bmi-suppl.4-2015-025] A study examining miRNAs in the plasma of chronically infected children identified 16 miRNAs to be upregulated in HBeAg+ compared to children with HBeAg−: miR-99a, miR-100, miR-122, miR-122\*, miR-125b, miR-192, miR-192\*, miR-193b, miR-194, miR-215, miR-365, miR-455-5p, miR-455-3p, miR-483-3p, miR-885-5p, and miR-1247.[@b183-bmi-suppl.4-2015-025] Another miRNA serum profiling study also identified miR-99a-5p, miR-122-5p, and miR-192-5p as significantly overexpressed between chronic hepatitis B adult patients and inactive carriers. Using an MiR-B-Index that normalized these three miRNAs to internal control miRNAs (miR-126, miR-320a, and miR-335), the same study showed that the serum miRNA profile of patients responding to pegylated (PEG)-IFN alpha resembled that of inactive carriers, while nonresponders and relapsers matched baseline measurements of patients with chronic hepatitis B.[@b184-bmi-suppl.4-2015-025] This comprehensive study illustrated that miRNAs could be useful not only in assessing disease status (inactive carriers vs. chronic hepatitis B patients) but also in identifying responders to certain treatments, such as PEG-IFN. The study also emphasized that although a single biomarker is desirable for simplicity and financial reasons, panels of biomarkers can also be effective in determining disease state and response to treatment. Further support for biomarker panels is provided by several studies.[@b177-bmi-suppl.4-2015-025],[@b185-bmi-suppl.4-2015-025],[@b186-bmi-suppl.4-2015-025] Notably, Li et al used a panel of 13 miRNAs to distinguish control patients from those with HBV infection (miR-10a, miR-223, miR-375, and miR-423), control patients from those with HBV-HCC (miR-23a, miR-23b, miR-92a, miR-342-3p, miR-375, and miR-423), patients with HBV from those with HCV infection (miR-92a up in HCV and miR-375 up in HBV), and patients with chronic HBV from those with HBV-positive HCC (miR-19a and miR-125b).[@b177-bmi-suppl.4-2015-025]

Liver injury can produce similar biomarker responses, regardless of the causative agent. An interesting miRNA profiling study by Ura et al examined the expression of 188 miRNAs from HBV-HCC, HCV-HCC, and normal patients. They identified 19 miRNAs that were differentially expressed between HBV and HCV.[@b187-bmi-suppl.4-2015-025] In all, 31 miRNAs were associated with liver disease, regardless of the virus, but 6 were specific for HBV and 13 for HCV. Notably, miR-105, miR-134, and miR-211 were over fourfold upregulated in HBV and miR-34c was over fourfold increased in HCV.[@b187-bmi-suppl.4-2015-025] However, other studies have produced conflicting results,[@b188-bmi-suppl.4-2015-025],[@b189-bmi-suppl.4-2015-025] and thus, the miRNAs identified are likely to need further validation.

### Role of miRNAs as therapeutics against HBV

The potential that miRNAs hold to serve as therapeutic agents against HBV has long been recognized,[@b190-bmi-suppl.4-2015-025]--[@b193-bmi-suppl.4-2015-025] and a number of studies have attempted to employ miRNA to combat HBV *in vivo*. The first *in vivo* result of antiviral RNAi activity used short hairpin RNAs (shRNAs), essentially, the pre-miRNA hairpin structure, in a study that targeted a mouse model of HBV infection using hydrodynamic delivery of HBV gene and shRNA vectors.[@b194-bmi-suppl.4-2015-025] Several other early studies also demonstrated inhibition of HBV by RNAi.[@b195-bmi-suppl.4-2015-025]--[@b201-bmi-suppl.4-2015-025] The use of 2′-OH-modified siRNAs was another approach that enhanced stability and inhibited infection in an *in vivo* mouse model of HBV replication.[@b202-bmi-suppl.4-2015-025],[@b203-bmi-suppl.4-2015-025] shRNAs were utilized in early studies,[@b204-bmi-suppl.4-2015-025]--[@b209-bmi-suppl.4-2015-025] but the RNA polymerase III-delivery method commonly used presented toxicity problems to the host.[@b210-bmi-suppl.4-2015-025] Thus, modified RNA polymerase II-dependent systems encoding pri-miRNAs were used that were expressed at lower levels due to the requirement for Drosha cleavage. These were not toxic and did not interfere with the endogenous miRNA production necessary for proper cell function.[@b201-bmi-suppl.4-2015-025],[@b211-bmi-suppl.4-2015-025]--[@b214-bmi-suppl.4-2015-025]

Multimeric miRNA expression cassettes have been used to effectively target multiple sites within the virus genome using mouse models of HBV infection,[@b214-bmi-suppl.4-2015-025] and a common delivery method for the miRNA therapeutic uses adeno-associated virus (AAV) or lentivirus systems.[@b215-bmi-suppl.4-2015-025],[@b216-bmi-suppl.4-2015-025] AAV-delivered miR-26a resulted in cell-cycle arrest *in vitro* through direct targeting of cyclins D2 and E2 in HCC cells. In addition, systemic intravenous administration of the AAV-miR-26a led to reduced HCC cell proliferation and tumor-specific apoptosis.[@b217-bmi-suppl.4-2015-025] In an HBV-HCC model, tumor growth was significantly decreased after lentiviral transduction of miRNA targeting HBsAg into HBV+ HepG2.2.15 cells before injection into nude mice.[@b218-bmi-suppl.4-2015-025] These and other experiments provide proof of concept that miRNAs downregulated in cancers could be reconstituted to normal levels to reduce tumor growth and that viral genes involved in tumor progression could be targeted by engineered miRNAs.

Hepatitis C virus
-----------------

The HCV is a small, enveloped, positive-strand RNA virus belonging to the *Flaviviridae* family. There are an estimated 170 million people infected worldwide, with up to 500,000 deaths annually as a result. The primary tropism of the virus is for human hepatocytes. Approximately 80% of those initially infected are asymptomatic, but only 15--25% of initial infections are cleared by the host immune system. The remainder results in chronic infections, 15--30% of which will eventually progress to cirrhosis in \~20 years. HCV chronic infection is also a significant cause of HCC.[@b142-bmi-suppl.4-2015-025]

As a cytoplasmic RNA virus, HCV is unable to encode miRNAs using traditional nuclear processing machinery, and no HCV-encoded miRNAs have yet been described. Additionally, encoding a miRNA within its genome would be a risky strategy for an RNA virus, as the miRNA processing cell machinery might target the genome for cleavage. HCV does encode suppressor of RNAi silencing proteins via the HCV core protein and envelope protein E2,[@b219-bmi-suppl.4-2015-025],[@b220-bmi-suppl.4-2015-025] and a plethora of host-encoded miRNAs have been described that interact with HCV and are differentially expressed during the course of an infection. In fact, as the disease progresses from initial infection all the way to HCC, corresponding changes in miRNA levels have been detected in profiling studies.[@b187-bmi-suppl.4-2015-025]--[@b189-bmi-suppl.4-2015-025],[@b221-bmi-suppl.4-2015-025]--[@b223-bmi-suppl.4-2015-025] If a reproducible pattern of specific host miRNAs could be documented as disease progression occurs, it could identify miRNAs as powerful biomarkers of HCV pathology. [Table 6](#t6-bmi-suppl.4-2015-025){ref-type="table"} provides a partial list of miRNAs shown to be differentially expressed or found to interact with HCV during infection.

Like HBV, most of the attention regarding miRNAs and HCV has centered around miR-122, which, as mentioned above, represents 50--70% of the miRNAs found in normal liver cells.[@b145-bmi-suppl.4-2015-025]--[@b147-bmi-suppl.4-2015-025] It is important to note that while miR-122 is an inhibitor of infection by HBV,[@b150-bmi-suppl.4-2015-025],[@b151-bmi-suppl.4-2015-025],[@b153-bmi-suppl.4-2015-025],[@b157-bmi-suppl.4-2015-025] it *aids* in the infection of host hepatocytes by HCV. During HCV infection, miR-122 is upregulated and protects the HCV genome by binding to and masking the 5′-UTR, protecting it from degradation, and promoting overall replication.[@b224-bmi-suppl.4-2015-025]--[@b226-bmi-suppl.4-2015-025] While bound to the HCV 5′-UTR, miR-122 can also recruit Ago2 to its 5′ end, which further stabilizes the genome and stimulates translation of HCV proteins.[@b227-bmi-suppl.4-2015-025]--[@b229-bmi-suppl.4-2015-025] Furthermore, miR-122 protects the 5′ end from degradation by Xrn1 exonuclease.[@b155-bmi-suppl.4-2015-025] The net result is an increase in HCV replication and translation of HCV proteins.

### Traditional detection methods and putative biomarkers of HCV infection

The initial testing for HCV is usually done by enzyme immunoassay to detect host antibodies directed against HCV.[@b230-bmi-suppl.4-2015-025] Liver damage associated with HCV is also screened for using ALT and AST enzyme tests.[@b230-bmi-suppl.4-2015-025],[@b231-bmi-suppl.4-2015-025] Positive results in initial screenings are usually confirmed via molecular testing to detect the presence of HCV RNA, sometimes followed by patient biopsy to assess the extent of liver damage, if necessary.[@b230-bmi-suppl.4-2015-025] As described above for HBV, liver biopsies are not without serious drawbacks.[@b173-bmi-suppl.4-2015-025],[@b174-bmi-suppl.4-2015-025]

Algorithms are also used that include a variety of additional criteria and biomarkers such as age, sex, levels of other liver enzymes, or platelet numbers. Examples include FirboTest and HepaScore.[@b232-bmi-suppl.4-2015-025],[@b233-bmi-suppl.4-2015-025] Unfortunately, many results fall in the *indeterminate* category or do not represent liver-specific injury. Several studies have suggested that miRNAs may be of great utility in differentiating liver diseases, and one study in particular showed miRNAs to be more discriminating than AST/ALT while differentiating between liver and muscle injury.[@b234-bmi-suppl.4-2015-025]

Compared to standard diagnostic methods, the potential advantages of using miRNAs as HCV biomarkers include the noninvasive nature of retrieval, generation of fairly rapid results, and possible lower costs compared to other methods. Profiling studies are often used as the first step in identifying candidate miRNAs that could serve as biomarkers, and there are already several studies that compare HCV-related disease states and healthy individuals.[@b187-bmi-suppl.4-2015-025]--[@b189-bmi-suppl.4-2015-025],[@b221-bmi-suppl.4-2015-025]--[@b223-bmi-suppl.4-2015-025],[@b235-bmi-suppl.4-2015-025] These studies have begun to reveal the potential of miRNAs to be a useful tool for diagnosing HCV-related disease as well as monitoring the progression or regression of the disease.

Several miRNAs are differentially regulated as a result of HCV or HCV-induced conditions ([Tables 7](#t7-bmi-suppl.4-2015-025){ref-type="table"} and [8](#t8-bmi-suppl.4-2015-025){ref-type="table"}). Notably, studies have demonstrated the utility of using miR-122 to identify HCV, HCC, and hepatocyte injury,[@b181-bmi-suppl.4-2015-025],[@b234-bmi-suppl.4-2015-025] and this miRNA is also extensively used to identify HBV status.[@b160-bmi-suppl.4-2015-025],[@b177-bmi-suppl.4-2015-025],[@b179-bmi-suppl.4-2015-025] Other host miRNAs directly target HCV genomic sequences: miR-199a reduces HCV replication by targeting the 5′-UTR of the genome internal ribosome entry site (IRES) region.[@b236-bmi-suppl.4-2015-025] Additionally, the expression of miRNA-196b appears to be upregulated by the IFN pathway and can thus inhibit HCV by directly targeting NS5A or by indirectly targeting BACH1 and HMOX1.[@b237-bmi-suppl.4-2015-025]--[@b239-bmi-suppl.4-2015-025] However, there have been conflicting results reporting whether it is upregulated or downregulated during infection,[@b239-bmi-suppl.4-2015-025]--[@b241-bmi-suppl.4-2015-025] possibly making its implementation as a biomarker difficult. As a way of effectively distinguishing HCV versus HBV infection, miR-92a and miR-375 are more highly upregulated in HCV+ or HBV+ patients, respectively. miR-10a and miR-125b are not upregulated in HCV+ but highly upregulated in HBV+ individuals,[@b177-bmi-suppl.4-2015-025] although miR-10a is upregulated in HCV-HCC cases.[@b223-bmi-suppl.4-2015-025] Several biomarkers overlap in these and other non-viral liver conditions, emphasizing the importance of biomarker panels to properly differentiate these diseases.

### miRNAs as therapeutics for HCV

Current therapeutics for HCV include the use of PEG-IFN and ribavirin,[@b242-bmi-suppl.4-2015-025]--[@b244-bmi-suppl.4-2015-025] and more recently, sofosbuvir, ledipasvir, and boceprevir have been used effectively.[@b245-bmi-suppl.4-2015-025]--[@b248-bmi-suppl.4-2015-025] While many therapies are successful, there are still a significant number of patients in whom the virus is not fully cleared.[@b249-bmi-suppl.4-2015-025],[@b250-bmi-suppl.4-2015-025] Additionally, therapies are costly, not easily accessible to all infected individuals, and can have severe side effects.[@b251-bmi-suppl.4-2015-025],[@b252-bmi-suppl.4-2015-025]

Recently, miR-122 has emerged as a promising candidate in the implementation of miRNAs as therapeutics. The observation that this abundant liver miRNA is upregulated and promotes replication during HCV infection made it an obvious choice to antagonize therapeutically. A small effector molecule against miR-122 inhibited HCV replication in liver cells,[@b253-bmi-suppl.4-2015-025] and Lanford et al used an antisense locked nucleic acid (LNA; an oligonucleotide with greater strength of binding due to chemical modification) derivative of miR-122 as a therapeutic in HCV-infected chimpanzees. A sharp reduction in HCV RNA and improved liver histology was observed without significant side effects or detectable resistance from the virus.[@b254-bmi-suppl.4-2015-025] Phase 1 clinical trials of miravirsen, an LNA that targets miR-122, were completed in 2009 by sponsor Santaris Pharma. In Phase 2a studies of null responders to PEG-IFN with HCV genotype 1 infection, miravirsen reduced mean HCV RNA levels up to three orders of magnitude with no drug-associated severe or serious adverse events.[@b255-bmi-suppl.4-2015-025] Notably, HCV RNA levels increased following cessation of the drug. Long-term administration studies are ongoing ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifiers NCT01727934 and NCT02031133). These results will possibly usher in a new era of miRNA-based biologics.

While the results using miR-122 are promising, there are still several other miRNAs worth considering to this end. Pedersen et al described mimics of five miRNAs (miR-196, miR-296, miR-351, miR-431, and miR-448) that reduced HCV replication and infection when transfected into HCV+ cells.[@b238-bmi-suppl.4-2015-025] Antagomir-mediated knockdown of miR-141 effectively inhibited HCV replication in infected hepatocytes.[@b256-bmi-suppl.4-2015-025] Moreover, the mimics of three miRNAs, miR-196b, miR-199a-3p, and miR-29, have been expected to function in anti-HCV therapy.[@b257-bmi-suppl.4-2015-025]

An interesting related approach was considered by Yang et al who created artificial miRNAs based on five preselected targets on the HCV genome. When introduced into cells, they dramatically reduced the replication of cell culture-propagated HCV without causing hepatocellular toxicity.[@b258-bmi-suppl.4-2015-025] This may suggest that knowledge of the viral target sequence may be just as valuable, if not more so, than targeting naturally occurring miRNAs. Since artificial miRNAs and their derivatives are relatively easy to create and introduce into a host, this could help alleviate the need for extensive profiling studies to identify aberrantly expressed miRNAs as targets.

Human papillomavirus
--------------------

HPV is a small, non-enveloped, double-stranded DNA virus that infects epithelial cells. Over 120 different types have been identified. While most infect cutaneous epithelium, \~40 types infect mucosal epithelium, some of which are associated with oncogenesis. Types 16 and 18 together account for \~70% of cervical cancer cases. HPV is also associated with less common cancers, including cancer of the anus, penis, vulva, and vagina. In the United States, HPV is the most common sexually transmitted disease. The virus is also associated with the vast majority of head and neck cancers in nonsmokers.[@b259-bmi-suppl.4-2015-025]

The majority of HPV infections are eventually cleared from the host, but a small proportion result in persistent infections that can progress to cervical intraepithelial neoplasias (CINs). High-grade CINs (CIN2 or CIN3) are considered a precursor to cervical cancer, which may occur within years or decades.[@b259-bmi-suppl.4-2015-025] As such, much effort has been invested to characterize the role of the virus in oncogenesis, particularly pertaining to the roles of viral oncoproteins E5, E6, and E7.

Recently, host miRNAs have also been implicated in the process. Several miRNAs have been identified as specifically targeted by E5, E6, or E7 ([Table 9](#t9-bmi-suppl.4-2015-025){ref-type="table"}), and their subsequent cellular effects in many cases have been characterized. E6 targets p53,[@b260-bmi-suppl.4-2015-025],[@b261-bmi-suppl.4-2015-025] a transcription factor that is thought to be used for transcription of many cellular miRNAs.[@b262-bmi-suppl.4-2015-025],[@b263-bmi-suppl.4-2015-025] As a result, many miRNAs may be drastically underexpressed and might lead to adverse cellular effects. miR-23b, miR-34a, miR-203, and miR-218 are all found to be downregulated in E6-expressing cells,[@b264-bmi-suppl.4-2015-025]--[@b269-bmi-suppl.4-2015-025] which is particularly noteworthy because of the association of these miRNAs with oncogenic processes, in part through direct or indirect effects of p53 inhibition.

Although all the above miRNAs have been implicated in cervical cancer, they have also been reported as tumor suppressors in a variety of other cancers: miR-23b in prostate, bladder, and breast cancers[@b270-bmi-suppl.4-2015-025]--[@b272-bmi-suppl.4-2015-025]; miR-34a in neuroblastomas, HCC, and ovarian, colon, pancreatic, and bladder cancers[@b266-bmi-suppl.4-2015-025],[@b273-bmi-suppl.4-2015-025]--[@b276-bmi-suppl.4-2015-025]; miR-203 in lung, prostate, and esophageal cancer, as well as leukemia and glioma[@b277-bmi-suppl.4-2015-025]--[@b279-bmi-suppl.4-2015-025]; and miR-218 in prostate, colon, gastric, and bladder cancer.[@b280-bmi-suppl.4-2015-025]--[@b282-bmi-suppl.4-2015-025]

E7 degrades the tumor suppressor protein pRB, which releases E2F from the pRB--E2F complex,[@b283-bmi-suppl.4-2015-025] freeing E2F to activate transcription. The promoter regions of several miRNAs contain E2F binding sites,[@b280-bmi-suppl.4-2015-025],[@b284-bmi-suppl.4-2015-025],[@b285-bmi-suppl.4-2015-025] which could possibly lead to adverse effects on the cell if oncogenic miRNAs are transactivated. In contrast to E6-induced miRNAs, most of the miRNAs shown to be dysregulated through the action of E7 are upregulated, such as miR-15b/16-1, miR-24, and miR-205.[@b286-bmi-suppl.4-2015-025]--[@b289-bmi-suppl.4-2015-025] The downregulation of miR-203 has been credited to the indirect blocking of the MAPK/PKC pathway by E7.[@b290-bmi-suppl.4-2015-025]

Less is known about the actions of E5 on cellular miRNAs. A recent study found that several miRNAs were altered in HPV16 E5-expressing HaCaT cells.[@b291-bmi-suppl.4-2015-025] Notably, the authors of that study found that miR-146a was induced, while miR-203 and miR-324-5p were repressed. miR-146a and miR-203 had previously been shown to be dysregulated in the same manner in cervical cancer tissues or HPV+ cell lines.[@b290-bmi-suppl.4-2015-025],[@b292-bmi-suppl.4-2015-025]--[@b300-bmi-suppl.4-2015-025]

### miRNAs as potential biomarkers of HPV infection and progression

It is suspected that the expression of many miRNAs may be altered during the course of HPV infection, possibly contributing to oncogenesis. Several studies have examined miRNAs dysregulated in cervical cancer or head and neck squamous cell carcinoma (HNSCC), two cancers that are likely to be the result of HPV infection. This section of our review focuses on those fewer studies that specifically addressed HPV+ cell lines or HPV+ cancer cells/tissues for the purposes of identifying HPV-specific biomarkers ([Table 10](#t10-bmi-suppl.4-2015-025){ref-type="table"}), pointing out when individual miRNAs have also been identified in cancerous cells or tissues with a possible contribution by HPV.

miR-21 has been implicated as an oncogenic miRNA for many cancers.[@b301-bmi-suppl.4-2015-025] Indeed, almost all profiling studies to date of cervical and head and neck cancers have found miR-21 to be overexpressed in the cancerous state,292,293,296,300,302--314 and miR-21 has been shown to be upregulated in HPV-related cancers as well.[@b308-bmi-suppl.4-2015-025],[@b315-bmi-suppl.4-2015-025] Lajer et al compared HPV+ and HPV− patients with tonsillar squamous cell carcinoma (TSCC) and found miR-21 to be upregulated in HPV+ patients. Additionally, miR-21 was upregulated in HPV+ or HPV− HNSCC as well as HPV+ cervical squamous cell carcinoma (CSCC),[@b315-bmi-suppl.4-2015-025] implying that it may serve as an HPV-specific biomarker as well as a general cancer biomarker. The fact that miR-21 overexpression is detectable in plasma makes it even more appealing as a biomarker.[@b308-bmi-suppl.4-2015-025]

Like miR-21, miR-31 is detectable in saliva[@b316-bmi-suppl.4-2015-025] and has been implicated as an oncogenic miRNA.[@b317-bmi-suppl.4-2015-025] Several oral cancer tissue profiling studies have found miR-31 to be upregulated,[@b293-bmi-suppl.4-2015-025],[@b304-bmi-suppl.4-2015-025],[@b309-bmi-suppl.4-2015-025],[@b310-bmi-suppl.4-2015-025] and it has also been documented to be upregulated in HPV+ cancers. A study comparing HPV+ oral squamous cell carcinoma (OSCC) patients to HPV− control patients found that miR-31 was the most upregulated miRNA of OSCC biopsies.[@b318-bmi-suppl.4-2015-025] Interestingly, a follow-up study by the same group comparing miRNA expression in HPV+ or HPV− TSCC tissue revealed that miR-31 was one of the most downregulated miRNAs in HPV+ TSCC,[@b315-bmi-suppl.4-2015-025] further indicating the potential utility of the miRNA in the differential diagnosis of HPV+ carcinomas.

Other interesting miRNAs were revealed in this study of HPV+ TSCC, including the upregulation of miR-363 and downregulation of miR-375. In accordance with these results, miR-363 has also been shown to be upregulated in both HPV+ and HPV− pharyngeal squamous cell carcinoma (PSCC) and in HPV16+ HNSCC cell lines.[@b318-bmi-suppl.4-2015-025],[@b319-bmi-suppl.4-2015-025] miR-375 has been found to be significantly downregulated in HNSCC and OSCC.[@b300-bmi-suppl.4-2015-025],[@b302-bmi-suppl.4-2015-025],[@b311-bmi-suppl.4-2015-025],[@b320-bmi-suppl.4-2015-025]

miR-155 is another miRNA that has been found to be upregulated in several oral cancer profiling studies[@b304-bmi-suppl.4-2015-025],[@b310-bmi-suppl.4-2015-025]--[@b312-bmi-suppl.4-2015-025],[@b321-bmi-suppl.4-2015-025]; however, it has been documented as being downregulated when comparing HPV− and HPV+ cell lines or oral cancer tissues with control tissues.[@b294-bmi-suppl.4-2015-025],[@b319-bmi-suppl.4-2015-025] It is possible that this miRNA may behave differently in tissue culture as compared to actual tissue. This was the case for miR-181a, which was found to be downregulated between HPV− versus HPV+ tissue culture,[@b319-bmi-suppl.4-2015-025] despite that several profiling studies using cancerous tissues have identified miR-181a as upregulated.[@b294-bmi-suppl.4-2015-025],[@b302-bmi-suppl.4-2015-025],[@b304-bmi-suppl.4-2015-025],[@b321-bmi-suppl.4-2015-025] Nonetheless, the consistent appearance of miR-155 in HPV-related conditions is compelling and worth further investigation.

Similarly, miR-203 has been shown to be upregulated or downregulated in different studies. miRNA was downregulated in keratinocyte cell lines expressing HPV oncoproteins,[@b290-bmi-suppl.4-2015-025],[@b291-bmi-suppl.4-2015-025] which is further supported by several profiling studies that used tissues from HNSCC or CSCC.[@b294-bmi-suppl.4-2015-025],[@b296-bmi-suppl.4-2015-025]--[@b300-bmi-suppl.4-2015-025],[@b306-bmi-suppl.4-2015-025] Martinez et al, however, found miR-203 to be upregulated when comparing HPV+ and HPV− keratinocytes.[@b269-bmi-suppl.4-2015-025] Nonetheless, the repeated appearance of miR-203 in HPV-related conditions warrants its inclusion in further studies as a potential biomarker. It is also noteworthy that it has been detected in plasma in patients with laryngeal squamous cell carcinoma (LSCC).[@b299-bmi-suppl.4-2015-025]

Other notably upregulated miRNAs are miR-200c and miR-205. When 28-fold increased, miR-200c was found to be the most overexpressed miRNA in HPV16+ cell lines compared to HPV− cell lines.[@b269-bmi-suppl.4-2015-025] miR-205 is known to be induced via E7 and has been shown to be upregulated in HPV+ cervical cells[@b286-bmi-suppl.4-2015-025] and in several oral cancer profiling studies, as well.[@b304-bmi-suppl.4-2015-025],[@b322-bmi-suppl.4-2015-025]--[@b324-bmi-suppl.4-2015-025] However, one study has indicated that miR-205 is downregulated in HNSCC and is significantly associated with poor survival.[@b303-bmi-suppl.4-2015-025]

In addition to the upregulated miRNAs mentioned above, several miRNAs have been shown to be downregulated during HPV infection. The expression of miR-143 and miR-145 is reduced in HPV+ cervical cancer cell lines compared to HPV− cell lines.[@b269-bmi-suppl.4-2015-025],[@b286-bmi-suppl.4-2015-025] Both miRNAs are similarly downregulated in tissues from patients with cervical carcinomas, hypopharyngeal squamous cell carcinoma (HSCC), LSCC, or HNSCC.[@b297-bmi-suppl.4-2015-025],[@b298-bmi-suppl.4-2015-025],[@b300-bmi-suppl.4-2015-025],[@b304-bmi-suppl.4-2015-025],[@b306-bmi-suppl.4-2015-025],[@b307-bmi-suppl.4-2015-025],[@b311-bmi-suppl.4-2015-025],[@b325-bmi-suppl.4-2015-025] miR-34a is known to be negatively regulated by the HPV E6 protein, and its expression was downregulated in HPV16+ cervical cells and HPV+ cervical tissue.[@b325-bmi-suppl.4-2015-025]--[@b327-bmi-suppl.4-2015-025] It has also been shown to be downregulated in OSCC.[@b294-bmi-suppl.4-2015-025],[@b305-bmi-suppl.4-2015-025]

One of the more promising HPV biomarkers may exist in miR-218, also regulated by the HPV E6 protein. It has been identified as significantly downregulated in multiple studies using HPV-infected cells.[@b269-bmi-suppl.4-2015-025],[@b300-bmi-suppl.4-2015-025],[@b319-bmi-suppl.4-2015-025] In fact, a study comparing HPV+ versus HPV− cervical cancer cell lines found miR-218 to be (the only) significantly underexpressed miRNA.[@b269-bmi-suppl.4-2015-025] It has been shown to be downregulated in HPV+ squamous cell carcinoma of the head and neck cell lines and in the HSCC tissue. Collectively, these studies identify miR-218 as a potential HPV-specific biomarker.

Human immunodeficiency virus
----------------------------

HIV is an enveloped lentivirus belonging to the *Retroviridae* family. There is much controversy concerning whether HIV actually encodes its own miRNA. As a nuclear RNA virus, HIV might reasonably avoid encoding miRNAs since Drosha-mediated excision of a pre-miRNA from the genome could induce the cleavage of the replicated viral RNA.[@b328-bmi-suppl.4-2015-025],[@b329-bmi-suppl.4-2015-025] Furthermore, it has been suggested that any HIV-1 miRNA would need to play an important evolutionary role in viral replication to compensate for the degradation of viral genomic RNAs by Drosha cleavage.[@b19-bmi-suppl.4-2015-025] On the other hand, HIV-1 might encode functional miRNAs because the viral genomic RNA is reverse transcribed in the cytoplasm into a double-stranded DNA molecule that is then imported into the nucleus for integration into the host genome.[@b330-bmi-suppl.4-2015-025] As mentioned above, RNA viruses have been successfully engineered to express functional miRNAs without reducing viral genome replication.[@b21-bmi-suppl.4-2015-025] Furthermore, bovine leukemia virus, a retrovirus, avoids Drosha-mediated cleavage of its genome by encoding miRNAs that are produced by RNA polymerase III. This creates miRNAs that are too short to be processed by Drosha/DGCR8 complexes and are instead processed directly by Dicer in the cytoplasm.[@b331-bmi-suppl.4-2015-025]

In 2004, five putative HIV miRNAs were computationally identified,[@b332-bmi-suppl.4-2015-025] and it was later reported that an HIV miRNA derived from the *nef*gene, termed miR-N367, targeted the long terminal repeat (LTR) U3 region.[@b333-bmi-suppl.4-2015-025],[@b334-bmi-suppl.4-2015-025] However, two reports subsequently reported that HIV miRNAs--including miR-N367--were not detectable by conventional sequencing of small RNAs in HIV-infected HeLa cells[@b18-bmi-suppl.4-2015-025] or persistently-infected ACH-2 T cells.[@b19-bmi-suppl.4-2015-025] Using in vitro studies, Klase et al reported that the HIV-1 TAR element, a hairpin structure \~50 nucleotides in length at the 5′ end of the viral genome, was processed by Dicer to create viral miRNA that was capable of inhibiting LTR-driven gene expression. This suggested a post transcriptional silencing method that could contribute to viral latency.[@b15-bmi-suppl.4-2015-025] Primer extension and RNase protection assays derived a TAR miRNA duplex that encoded miR-TAR-5p and miR-TAR-3p,[@b17-bmi-suppl.4-2015-025] and in another study by Klase et al, HIV-1 miR-TAR-3p/5p was found to protect infected cells from apoptosis.[@b16-bmi-suppl.4-2015-025] Another HIV-encoded miRNA, miR-H3, was recently identified through computational prediction and deep sequencing. Deletion assays suggested that it targeted the HIV 5′ LTR TATA box to activate viral transcription.[@b335-bmi-suppl.4-2015-025]

Deep sequencing studies of HIV-infected T cells identified several HIV small RNAs, including an 18-nucleotide RNA antisense to the HIV tRNA primer binding site.[@b336-bmi-suppl.4-2015-025] Similarly, Schopman et al used deep sequencing to identify small RNAs from HIV-infected T cells. One set of small RNAs originated from secondary hairpin structures formed by the viral genomic RNA and were attributed as a class of miRNAs. Although they were found to be in very low proportion in the total small RNAs, three of them were able to prevent luciferase activity when cloned into a reporter construct, including the previously reported TAR miRNA. Antagomirs also increased HIV replication of infected 293T cells.[@b337-bmi-suppl.4-2015-025]

A recent study by Whisnant et al pointed out that miRNAs \<22 nucleotides are more consistent with RNA breakdown products than other miRNAs and that a decisive seed region on the 5′ end of the miRNA must be considered.[@b20-bmi-suppl.4-2015-025] They also highlighted that low-frequency miRNAs, representing \<0.1% of the total miRNA pool, are not likely to be biologically relevant.[@b338-bmi-suppl.4-2015-025] They examined small RNAs in two HIV-infected cell lines, human primary CD4+ peripheral blood mononuclear cells (PBMCs), and human macrophages, and did not identify any HIV miRNAs.[@b20-bmi-suppl.4-2015-025] By using PAR-CLIP, they found a small subset of expressed cellular miRNAs that exhibited complementarity to HIV genome sequences. However, they determined that these miRNAs are largely unable to interact with the HIV RNA genome due to extensive viral secondary structures. Since HIV-1 has been implicated in the induction of several cellular miRNAs from infected cells (described below), this finding generates another layer of controversy in the matter. Together, these studies emphasize that additional confirmatory evidence is needed to establish a body of evidence to support or refute whether HIV-1 indeed encodes its own miRNA.

### Cellular miRNAs induced by HIV-1 infection

Studies have begun to shed light on the involvement of cellular miRNAs during HIV-1 infection. As mentioned above, additional studies will be needed to verify the biological relevance of these antisense oligonucleotides at the concentrations found in infected cells. For biomarker discovery, the relative presence or absence of miRNAs (or breakdown products) during infection is a more important consideration than their absolute concentration, as long as they are consistently detectable in a validated manner.

During HIV infection, several cellular miRNAs have been reported to be modulated that indirectly impact the replication of the virus. In 2007, Triboulet et al used microarray studies of HIV-infected Jurkat or PBMC to identify 11 cellular miRNAs that were upregulated upon infection and were dependent upon Drosha and Dicer machinery. Viral replication occurred faster in the absence of these miRNAs. Notably, miR-122, miR-297, miR-370, and miR-373\* were only expressed in HIV+ cells, while the miR-17/92 cluster (that includes miR-17-5p/3p, miR-18, miR-19a, miR-19b-1, miR-20a, and miR-92-1) was downregulated.[@b339-bmi-suppl.4-2015-025]

A challenge of using PBMCs to examine HIV-associated cellular miRNAs is that miRNAs are expressed differently in the various peripheral blood cells in the context of different environments. In an attempt to address this concern, Chang et al infected the CD4+ SUP-T1 T cell line with HIV-1 or UV-inactivated HIV-1 and used deep sequencing to identify miRNAs. At 24 hours post infection, 65 and 39 cellular miRNAs were upregulated or downregulated, respectively, in the HIV-1-infected cells.[@b340-bmi-suppl.4-2015-025] Similarly, HIV-1 infection of the CEMx174 hybrid B/T cell line resulted in the increased or decreased expression of 72 and 106 miRNAs, respectively, as assessed by the miRNA microarray.[@b341-bmi-suppl.4-2015-025] The results varied with different cell types or HIV strains, making comparison of the studies difficult.

In addition to affecting viral replication, cellular miRNAs have also been reported to directly target HIV-1 regulatory and accessory genes. A cluster of cellular miRNAs have been shown to target the 3′ end of the HIV-1 RNA, common to nearly all HIV-1 mRNA 3′-UTRs, to inhibit HIV-1 infection of primary CD4 T cells. Termed the "anti-HIV miRNAs," this cluster includes miR-28, miR-125b, miR-150, miR-223, and miR-382.[@b342-bmi-suppl.4-2015-025] Combined inhibition of these five miRNAs increased virus production in CD4 T cells isolated from HIV-1+ individuals on highly active antiretroviral therapy (HAART), indicating the miRNAs may be involved in maintaining latent infection in resting CD4 T cells. Furthermore, another group has shown that miR-150 and miR-223 are expressed at high levels in CD4+ T cells isolated from healthy controls compared with the HIV-1-infected individuals.[@b343-bmi-suppl.4-2015-025] A study using microarray to examine miRNA levels in the PBMC of HIV-1+ individuals with high viral load found that miR-223 was downregulated in this patient population, but miR-150 expression was unchanged.[@b344-bmi-suppl.4-2015-025]

It has been speculated that the anti-HIV miRNAs may be reduced in the differentiation of monocytes to macrophages, thereby creating an HIV-promoting intracellular environment. However, microarray studies showed that only miR-223 exhibited downregulation upon monocyte differentiation into macrophages. Meanwhile, miR-28-3p expression only slightly declined, miR-125b and miR-382 did not differ from background levels, and miR-150 was strongly upregulated.[@b345-bmi-suppl.4-2015-025]

Several studies have examined the role of the mi-R29 family during HIV infection, and target sites for miR-29a and miR-29b have been predicted within the HIV-1 *nef* 3′-UTR.[@b346-bmi-suppl.4-2015-025],[@b347-bmi-suppl.4-2015-025] Inhibiting miR-29a in 293T cells enhanced virus production and increased infectivity, while an miR-29a mimic suppressed HIV-1 production.[@b346-bmi-suppl.4-2015-025] In support of this, Patel et al noted that miR-29a levels were higher in PBMCs from control patients than from HIV+ patients, suggesting a possible role for miR-29a in HIV latency. Interestingly, plasma levels of miR-29a showed an opposite trend.[@b348-bmi-suppl.4-2015-025]

### miRNAs as potential biomarkers of HIV infection

Several groups have examined the regulation of cellular miRNAs during HIV infection to validate the potential of miRNAs as biomarkers ([Table 11](#t11-bmi-suppl.4-2015-025){ref-type="table"}). Moreover, recent studies have specifically examined the potential of miRNAs to distinguish between different groups of HIV-infected individuals. Munshi et al recently analyzed miR-16, miR-146b-5p, miR-150, miR-191, and miR-223 levels in the PBMCs and serum of HIV/AIDS patients in different stages of disease. miR-150 and miR-146b-5p were found to distinguish HIV+ individuals as well as those on HAART or developing drug resistance. The levels of miR-150 were found to be decreased in the PBMCs of HIV/AIDS patients before treatment, and HAART was able to restore levels of miR-150. Individuals who developed drug resistance reduced miR-150 expression to the levels observed in the symptomatic HIV/AIDS patients.[@b349-bmi-suppl.4-2015-025] In contrast, plasma levels of miR-150 were increased during infection and reduced upon treatment, prompting the authors to propose that miR-150 in the plasma may be derived from damaged tissues or released exosomes. A positive trend was also generally observed between PBMC miR-150 and CD4 T cell counts.

Some individuals infected with HIV, known as elite suppressors (ES), maintain an undetectable viral load and high CD4 T cell counts in the absence of any treatment. A study that characterized the miRNAs present in the PBMCs of ES versus untreated HIV/AIDS patients determined that the two groups actually share expression patterns of several miRNAs, although a few miRNAs were differentially expressed. miR-31, miR-31\*, and miR-150 were significantly downregulated, while miR-155 and miR-22 were moderately upregulated in active HIV/AIDS versus ES patients.[@b350-bmi-suppl.4-2015-025] This study also found a correlation of particular miRNAs with CD4 T cells counts in infected individuals compared to uninfected controls: miR-181b (negative) and miR-31, miR-31\*, miR-29a, and miR-150 (positive) all significantly correlated with CD4 T cell count (*P* \< 0.05). Recently, Reynoso et al performed a similar study examining miRNAs in the plasma of ES versus chronically infected individuals and normal donors. No significant differences were noted between normal and ES donors, although miR-29b-3p, miR-33a-5p, and miR-146a-5p were upregulated in ES versus chronically infected patients. Several miRNAs were also identified that correlated with CD4 T cell counts.[@b351-bmi-suppl.4-2015-025]

While viral titers and CD4 T cell counts are important for predicting disease progression, it has been suggested that CD4 T cell counts do not necessarily correlate well with virologic failure in patients being treated with ART,[@b352-bmi-suppl.4-2015-025] emphasizing the importance of the characterization and validation of potential HIV biomarkers.

### Potential miRNA therapeutics for HIV

At first thought, the cluster of anti-HIV miRNAs (miR-28, miR-125b, miR-150, miR-223, and miR-382) is of interest as potential antiretroviral drugs due to their reported ability to target HIV-1 mRNAs. However, several of these miRNAs are expressed in normal CD4 T cells,[@b353-bmi-suppl.4-2015-025] which are still capable of being infected by HIV. Recently, Whisnant et al found that HIV-1 transcripts are refractory to miRNA binding, likely due to secondary structure of viral mRNAs.[@b20-bmi-suppl.4-2015-025] This implied that these anti-HIV miRNAs may not be able to target the virus directly. This does not preclude their possible role, however, in modulating expression of genes that could create a cellular environment that is not susceptible or permissive to infection. Considering that a single miRNA is capable of affecting the transcription of many genes and therefore possibly inducing off-target effects, additional research is warranted concerning the utility of miRNAs as antiretroviral drugs.

Concluding Remarks
==================

Over 200 biomarker-related clinical trials involving miRNAs are listed on the [Clinicaltrials.gov](http://Clinicaltrials.gov) website (<https://clinicaltrials.gov/ct2/results?term=miRNA>), demonstrating that miRNAs continue to have great potential as biomarkers of diagnosis, disease progression, and treatment efficacy. As such, the use of miRNA biomarkers during diseases of viral origin also warrants further investigation. Several DNA viruses of clinical importance, namely, herpesviruses and polyomaviruses, encode unique viral miRNAs that could prove promising to differentiate viruses that have similar clinical symptoms. The use of miRNAs specifically expressed at different stages of infection could also help in accurately determining disease status. For the RNA viruses or retroviruses described above, profiling panels of cellular miRNAs could provide a means of identifying viruses or classifying disease stage. miRNAs that can be detected in PBMCs, plasma, or exosomes and mirror expression at the local site of infection or pathology are particularly attractive, providing a means to avoid invasive biopsies and better monitor disease using less-invasive methods. However, future miRNA assays based upon next-generation sequencing will require additional technical expertise and standardization. In addition, the presence of specific miRNAs in individuals of different backgrounds has not been thoroughly studied, and the conservation of miRNAs between clinical strains of the same virus also needs to be further explored.

Elucidating the biological functions of specific miRNAs has allowed us to contemplate the role of specific miRNAs as therapeutics or as therapeutic targets. However, drugs based upon RNAi have not been without multiple technical difficulties, including vehicle design, antisense oligonucleotide biostability, targeted delivery to cells of interest (and to necessary intracellular compartments), and off-target effects. Nonetheless, new strategies have been and continue to be developed to combat these initial roadblocks and build better therapeutics.[@b354-bmi-suppl.4-2015-025],[@b355-bmi-suppl.4-2015-025] Preliminary results from Phase 2a studies of miravirsen, an LNA that targets miR-122 during HCV infection, are cautiously promising.[@b255-bmi-suppl.4-2015-025] The results of additional clinical trials of miravirsen and other antagomirs will be of great interest in ascertaining the therapeutic potential of miRNAs and their inhibitors.
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![Genomic location of selected HSV-1 pre-miRNAs.\
**Note:** Figure modified from Nicoll MP, Proença JT, Efstathiou S. The molecular basis of herpes simplex virus latency. *FEMS Microbiol Rev*. 2012;36:684--706 with permission of Oxford University Press on behalf of the Federation of European Microbiological Societies.[@b446-bmi-suppl.4-2015-025]](bmi-suppl.4-2015-025f1){#f1-bmi-suppl.4-2015-025}

![Genomic location of KSHV pre-miRNAs. KSHV pre-miRNAs cluster within the KLAR, which also contains genes for LANA, v-Cyclin, v-FLiP, and Kaposin. All the miRNAs map to the K12 locus: miR-K12-1 through miR-K12-9 and miR-K12-11 are encoded within the K12 intron, while miR-K12-10 and miR-K12-12 map to a K12 open reading frame and the 3′-UTR, respectively.\
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###### 

Approaches used by miRNA target prediction software tools.

                 THERMODYNAMIC   EVOLUTIONARY   PROBABILISTIC   SEQUENCE-BASED   REFERENCE
  -------------- --------------- -------------- --------------- ---------------- ------------------------------
  miRmap         X               X              X               X                [@b356-bmi-suppl.4-2015-025]
  TargetScan                     X                              X                [@b6-bmi-suppl.4-2015-025]
  PITA           X                                                               [@b357-bmi-suppl.4-2015-025]
  PicTar         X               X              X                                [@b358-bmi-suppl.4-2015-025]
  miRanda        X                                                               [@b359-bmi-suppl.4-2015-025]
  RNAhybrid      X                                                               [@b360-bmi-suppl.4-2015-025]
  DIANA-microT   X               X                                               [@b361-bmi-suppl.4-2015-025]
  EIMMo                          X              X                                [@b362-bmi-suppl.4-2015-025]
  PACMIT         X                              X                                [@b363-bmi-suppl.4-2015-025]

**Note:** Table modified from Charles E. Vejnar, Evgeny M. Zdobnov. miRmap: Comprehensive prediction of microRNA target repression strength. *Nucl Acids Res*. 2007;40(22):11673--11683, with permission of Oxford University Press under a CC BY 3.0 license.

###### 

Notable herpesvirus-encoded miRNAs.

  HERPESVIRUS                                            miRNA                                                     mRNA TARGET                                                 REFERENCES
  ------------------------------------------------------ --------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------
  HSV-1                                                  miR-h2                                                    *ICP0*, a transactivator of IE, E, and L genes              [@b31-bmi-suppl.4-2015-025],[@b32-bmi-suppl.4-2015-025]
  miR-h4                                                 *ICP34.5*, a neurovirulence factor and immune inhibitor   [@b33-bmi-suppl.4-2015-025]                                 
  miR-h6                                                 *ICP4*, a transactivator of E and L genes                 [@b31-bmi-suppl.4-2015-025]                                 
  HSV-2                                                  miR-h2                                                    HSV1-miR-H2 ortholog; represses *ICP0*                      [@b32-bmi-suppl.4-2015-025]
  miR-h3                                                 *ICP34.5*                                                 [@b32-bmi-suppl.4-2015-025],[@b38-bmi-suppl.4-2015-025]     
  miR-h4                                                 *ICP34.5*                                                 [@b32-bmi-suppl.4-2015-025],[@b38-bmi-suppl.4-2015-025]     
  VZV                                                    none reported                                                                                                         
  EBV                                                    miR-BART2                                                 *BALF5*, the viral DNA polymerase                           [@b12-bmi-suppl.4-2015-025],[@b54-bmi-suppl.4-2015-025]
  miR-BART3, -BART5,-BART16, -BART17, -BART19, -BART20   *LMP1*, a viral gene that promotes cell survival          [@b55-bmi-suppl.4-2015-025]--[@b57-bmi-suppl.4-2015-025]    
  miR-BART5, -BART19                                     Cellular *PUMA*, a pro-apoptotic gene                     [@b55-bmi-suppl.4-2015-025],[@b59-bmi-suppl.4-2015-025]     
  miR-BART2                                              Cellular *MICB*, a stress-induced NK cell ligand          [@b55-bmi-suppl.4-2015-025],[@b63-bmi-suppl.4-2015-025]     
  miR-BART18                                             Cellular *CBP*, involved in type 1 IFN production         [@b65-bmi-suppl.4-2015-025]                                 
  HCMV                                                   miR- UL112                                                Targets HCMV genes IE1, IE72, UL112/113, UL114, UL120/121   [@b94-bmi-suppl.4-2015-025]--[@b96-bmi-suppl.4-2015-025]
  miR- UL112                                             Cellular *MICB*, a stress-induced NK cell ligand          [@b63-bmi-suppl.4-2015-025],[@b101-bmi-suppl.4-2015-025]    
  miR- UL148D                                            Cellular *RANTES*, a T cell-attracting chemokine          [@b102-bmi-suppl.4-2015-025]                                
  HHV-6B                                                 miR-Ro6--1                                                Antisense to B3 IE ORF; function unknown                    [@b104-bmi-suppl.4-2015-025]
  miR-Ro6--2                                             Antisense to B2 IE ORF; function unknown                  [@b104-bmi-suppl.4-2015-025]                                
  miR-Ro6--3                                             Antisense to B1 IE ORF; function unknown                  [@b104-bmi-suppl.4-2015-025]                                
  miR-Ro6--4                                             Function unknown                                          [@b104-bmi-suppl.4-2015-025]                                
  HHV-7                                                  None reported                                                                                                         
  KSHV                                                   miR-K12--9, miR-K12--7                                    RTA, the activator of the latent-lytic switch               [@b72-bmi-suppl.4-2015-025],[@b73-bmi-suppl.4-2015-025]
  miR-K12--1                                             Cellular *p21*, involved in cell cycle arrest             [@b82-bmi-suppl.4-2015-025]                                 
  miR-K12--7                                             Cellular *MICB*, a stress-induced NK cell ligand          [@b63-bmi-suppl.4-2015-025]                                 
  miR-K12--12                                            Cellular *CBP*, involved in Type 1 IFN production         [@b65-bmi-suppl.4-2015-025]                                 

###### 

Summary of human polyomavirus-encoded miRNAs.

  VIRUS   miRNA        miRBASE No.   GENOMIC POSITION   TARGET        REFERENCES
  ------- ------------ ------------- ------------------ ------------- -----------------------------------------------------------
  JCPyV   jcv-mir-J1   MI0009980     3' end of LTAg     LTAg, ULBP3   [@b130-bmi-suppl.4-2015-025],[@b134-bmi-suppl.4-2015-025]
  BKPyV   bkv-mir-B1   MI0009981     3' end of LTAg     LTAg, ULBP3   [@b130-bmi-suppl.4-2015-025],[@b134-bmi-suppl.4-2015-025]
  MCPyV   mcv-mir-M1   MI0010647     Middle of LTAg     LTAg          [@b133-bmi-suppl.4-2015-025],[@b138-bmi-suppl.4-2015-025]

###### 

Host miRNAs involved in HBV-related health conditions.

  miRNA               TARGET                                        EFFECT                                                                   REFERENCES
  ------------------- --------------------------------------------- ------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------
  miR-1               FXRA, HDAC4, MET                              Increase HBV transcription                                               [@b165-bmi-suppl.4-2015-025],[@b166-bmi-suppl.4-2015-025]
  miR-15a/16          HBV RNA, BCL2, CCND1 (host), NCOR2            HBV RNA is sponged; prevents apoptosis                                   [@b159-bmi-suppl.4-2015-025],[@b161-bmi-suppl.4-2015-025],[@b162-bmi-suppl.4-2015-025],[@b364-bmi-suppl.4-2015-025]
  miR-17/92 cluster   HBV RNA, E2F1, E2F3                           Promotes HCC proliferation                                               [@b365-bmi-suppl.4-2015-025],[@b366-bmi-suppl.4-2015-025]
  miR-18a             ESR1                                          Promotes HCC proliferation                                               [@b367-bmi-suppl.4-2015-025]
  miR-21              PTEN, PDCD4                                                                                                            [@b366-bmi-suppl.4-2015-025],[@b368-bmi-suppl.4-2015-025],[@b369-bmi-suppl.4-2015-025]
  miR-22              HDAC4, ESR1, CDKN1 A                          Inhibits HBV replication                                                 [@b370-bmi-suppl.4-2015-025]--[@b372-bmi-suppl.4-2015-025]
  miR-23b             PLAU, MET                                                                                                              [@b373-bmi-suppl.4-2015-025]
  miR-26a             ESR1, IL6, CCND2, CCNE2                                                                                                [@b374-bmi-suppl.4-2015-025],[@b375-bmi-suppl.4-2015-025]
  miR-29a             PTEN                                                                                                                   [@b376-bmi-suppl.4-2015-025]
  miR-29c             TNFAIP3                                       Tumor suppressor                                                         [@b377-bmi-suppl.4-2015-025]
  miR-34a             CCL22, MET                                    Inhibits HBV                                                             [@b378-bmi-suppl.4-2015-025]
  miR-99a             IGF1R, MTOR                                                                                                            [@b379-bmi-suppl.4-2015-025]
  miR-101             DNMT3A, FOS, MCL1, EZH2                                                                                                [@b380-bmi-suppl.4-2015-025]--[@b384-bmi-suppl.4-2015-025]
  miR-122             CCNG1, HMOX1, HBV mRNA                        Inhibits HBV replication and translation; increased HBV core stability   [@b153-bmi-suppl.4-2015-025],[@b154-bmi-suppl.4-2015-025],[@b156-bmi-suppl.4-2015-025],[@b160-bmi-suppl.4-2015-025],[@b161-bmi-suppl.4-2015-025]
  miR-125a-5p         HBV S gene, ERBB2                             Reduced expression of HBsAg; inhibits cell proliferation                 [@b164-bmi-suppl.4-2015-025],[@b385-bmi-suppl.4-2015-025]--[@b387-bmi-suppl.4-2015-025]
  miR-141             PPARA                                         Inhibits HBV replication                                                 [@b388-bmi-suppl.4-2015-025]
  miR-143             FNDC3B                                                                                                                 [@b389-bmi-suppl.4-2015-025]
  miR-145             HDAC2, ADAM17                                                                                                          [@b390-bmi-suppl.4-2015-025],[@b391-bmi-suppl.4-2015-025]
  miR-146a            STAT1                                         Promotes HBV infection                                                   [@b392-bmi-suppl.4-2015-025]
  miR-148a            DNMT1, HPIP, MET                              Loss of repression of HBV transcription                                  [@b168-bmi-suppl.4-2015-025],[@b240-bmi-suppl.4-2015-025],[@b393-bmi-suppl.4-2015-025]
  miR-152             DNMT1                                         Loss of repression of HBV transcription                                  [@b240-bmi-suppl.4-2015-025],[@b394-bmi-suppl.4-2015-025]
  miR-155             CEBPB, SOCS1, SOX6                            Decreases HBV transcription; increases host immune response              [@b395-bmi-suppl.4-2015-025],[@b396-bmi-suppl.4-2015-025]
  miR-199-3p          PAK4, MTOR, MET, HBsAg mRNA                   Inhibits HBV replication                                                 [@b163-bmi-suppl.4-2015-025],[@b397-bmi-suppl.4-2015-025]--[@b399-bmi-suppl.4-2015-025]
  miR-199a            HBV S region                                  Inhibits HBV replication                                                 [@b163-bmi-suppl.4-2015-025]
  miR-205             HBX mRNA                                      Inhibits HBV                                                             [@b400-bmi-suppl.4-2015-025]
  miR-210             AIFM3, HBsAg mRNA, HBV Pre-S1 region          Reduces HBsAg; inhibits HBV replication                                  [@b163-bmi-suppl.4-2015-025]
  miR-222             PPP2R2 A                                                                                                               [@b401-bmi-suppl.4-2015-025]
  miR-224             API5, ARHGAP9, ARHGAP12, SMAD4                Inhibits apoptosis; promotes metastasis                                  [@b402-bmi-suppl.4-2015-025]--[@b404-bmi-suppl.4-2015-025]
  miR-372             PRKACB, NF1B                                  Decreases HBV transcription; increases HBV expression                    [@b405-bmi-suppl.4-2015-025],[@b406-bmi-suppl.4-2015-025]
  miR-501             HBXIP                                         Promotes HBV replication                                                 [@b407-bmi-suppl.4-2015-025]
  miR-548             IFNL1                                         Promotes HBV infection                                                   [@b408-bmi-suppl.4-2015-025]
  miR-602             RASSF1 A                                      Oncogenic                                                                [@b409-bmi-suppl.4-2015-025]
  let-7 family        STAT3, COL1A2, MYC, NGF, BCL2L1, RAS, HMGA2   Increases cell proliferation                                             [@b364-bmi-suppl.4-2015-025],[@b410-bmi-suppl.4-2015-025],[@b411-bmi-suppl.4-2015-025]

###### 

Host miRNAs reported to be differentially expressed in serum/plasma during HBV infection.

  miRNA UPREGULATED                                                                                                 miRNA DOWN-REGULATED                 REFERENCES
  ----------------------------------------------------------------------------------------------------------------- ------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  miR-10a, miR-23a/b, miR-99a, miR-122, miR-150, miR-223, miR-342-3p, miR-375, miR-423, miR-572, miR-575, miR-638   miR-15a, miR-16-1, miR-21, miR-744   [@b177-bmi-suppl.4-2015-025],[@b178-bmi-suppl.4-2015-025],[@b180-bmi-suppl.4-2015-025],[@b182-bmi-suppl.4-2015-025],[@b183-bmi-suppl.4-2015-025],[@b412-bmi-suppl.4-2015-025]--[@b414-bmi-suppl.4-2015-025]

###### 

miRNAs involved in HCV infection.

  miRNA            TARGET                                                            EFFECT                                                                                                            REFERENCES
  ---------------- ----------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  miR-21           SMAD7                                                             Increases fbrogenesis                                                                                             [@b415-bmi-suppl.4-2015-025]
  miR-26a          CCND2, CCNE2                                                      Inhibits cell proliferation                                                                                       [@b217-bmi-suppl.4-2015-025]
  miR-27a          RXRA, ABCA1                                                       Reduces production of HCV virions                                                                                 [@b416-bmi-suppl.4-2015-025]
  miR-29           Unknown                                                           Loss leads to fbrosis                                                                                             [@b417-bmi-suppl.4-2015-025]
  miR-30d          GNAI1                                                             Promotes metastasis                                                                                               [@b418-bmi-suppl.4-2015-025]
  miR-101          MCL1, FOS                                                         Promotes apoptosis                                                                                                [@b383-bmi-suppl.4-2015-025]
  miR-122          5' UTR of HCV genome, XRN1, AGO2, CCNG1, SOCS3 promoter, ADAM17   Promotes replication, protects HCV 5' UTR, stabilizes HCV 5' UTR, promotes HCV replication, inhibits metastasis   [@b155-bmi-suppl.4-2015-025],[@b225-bmi-suppl.4-2015-025],[@b226-bmi-suppl.4-2015-025],[@b228-bmi-suppl.4-2015-025],[@b229-bmi-suppl.4-2015-025],[@b419-bmi-suppl.4-2015-025]--[@b421-bmi-suppl.4-2015-025]
  miR-124          ROCK2, EZH2, SMYD3                                                Tumor suppressor                                                                                                  [@b422-bmi-suppl.4-2015-025],[@b423-bmi-suppl.4-2015-025]
  miR-130a         IFITM1                                                            Increases HCV replication                                                                                         [@b424-bmi-suppl.4-2015-025]
  miR-139          ROCK2                                                             Inhibits metastasis                                                                                               [@b425-bmi-suppl.4-2015-025]
  miR-141          DLC1                                                              Increases HCV replication                                                                                         [@b256-bmi-suppl.4-2015-025]
  miR-155          APC                                                               Promotes proliferation and tumorigenesis                                                                          [@b426-bmi-suppl.4-2015-025]
  miR-194          CD81                                                              Inhibits HCV entry                                                                                                [@b427-bmi-suppl.4-2015-025]
  miR-196 family   HCV NS5A, BACH1                                                   Inhibits HCV replication and RNA/protein expression                                                               [@b237-bmi-suppl.4-2015-025],[@b238-bmi-suppl.4-2015-025]
  miR-199a         HCV 5' UTR IRES                                                   Inhibits HCV replication                                                                                          [@b236-bmi-suppl.4-2015-025]
  miR-221          CDKN1B, CDKN1C, BMF                                               Promotes cell proliferation, inhibits apoptosis                                                                   [@b428-bmi-suppl.4-2015-025],[@b429-bmi-suppl.4-2015-025]
  miR-448          HCV core region                                                   Inhibits HCV replication                                                                                          [@b238-bmi-suppl.4-2015-025]
  miR-449a         NOTCH1                                                            Promotes infammation                                                                                              [@b430-bmi-suppl.4-2015-025]
  let-7b           HCV NS5B and 5' UTR                                               Inhibits HCV infection                                                                                            [@b431-bmi-suppl.4-2015-025]
  let-7g           MYC, CDKN2A, COL1A2                                               Inhibits proliferation, suppresses metastasis                                                                     [@b410-bmi-suppl.4-2015-025],[@b432-bmi-suppl.4-2015-025]

###### 

Host miRNAs upregulated during HCV infection.

  COMPARTMENT           miRnA UPREGULATED                                           REFERENCES
  --------------------- ----------------------------------------------------------- ----------------------------------------------------------------------------------------
  Serum                 miR-20a, miR-92a, miR-122, miR-134a, miR-320c, miR-483-5p   [@b181-bmi-suppl.4-2015-025],[@b433-bmi-suppl.4-2015-025],[@b434-bmi-suppl.4-2015-025]
  Infected cell lines   miR-192, miR-193b, miR-194, miR-215, miR-585, miR-768-5p    [@b222-bmi-suppl.4-2015-025],[@b435-bmi-suppl.4-2015-025],[@b436-bmi-suppl.4-2015-025]

###### 

Host miRNAs differentially expressed in liver tissue biopsies during HCV infection, HCC, or HCV-associated HCC.

  CONDITION   miRnA UPREGULATED                                     miRnA DOWNREGULATED                  REFERENCES
  ----------- ----------------------------------------------------- ------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  HCV         miR-34c, miR-130a, miR-141, miR-155                   miR-29, miR-449a                     [@b187-bmi-suppl.4-2015-025],[@b256-bmi-suppl.4-2015-025],[@b417-bmi-suppl.4-2015-025],[@b424-bmi-suppl.4-2015-025],[@b426-bmi-suppl.4-2015-025],[@b430-bmi-suppl.4-2015-025]
  HCC         miR-181, miR-199a, miR-221, miR-301                   miR-29, miR-101, miR-139, let-7g     [@b188-bmi-suppl.4-2015-025],[@b383-bmi-suppl.4-2015-025],[@b410-bmi-suppl.4-2015-025],[@b425-bmi-suppl.4-2015-025],[@b429-bmi-suppl.4-2015-025],[@b437-bmi-suppl.4-2015-025],[@b438-bmi-suppl.4-2015-025]
  HCV-HCC     miR-10a, miR-21, miR-27a, miR-100, miR-122, miR-155   miR-122, miR-124, miR-145, miR-198   [@b188-bmi-suppl.4-2015-025],[@b223-bmi-suppl.4-2015-025],[@b224-bmi-suppl.4-2015-025],[@b254-bmi-suppl.4-2015-025],[@b364-bmi-suppl.4-2015-025],[@b415-bmi-suppl.4-2015-025], [@b416-bmi-suppl.4-2015-025],[@b423-bmi-suppl.4-2015-025],[@b426-bmi-suppl.4-2015-025]

###### 

HPV proteins known to alter host miRNAs.

  HPV PROTEIN   miRNA TARGET   EFFECt (UP/DOWN)                                                      POTENTIAL CELLULAR EFFECT                                                                 REFERENCES
  ------------- -------------- --------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ------------------------------
  e5            miR-146a       Up                                                                    Suppression of immune response, increased cell proliferation                              [@b291-bmi-suppl.4-2015-025]
  miR-203       Down           Deregulation of p63--increased cell proliferation                     [@b291-bmi-suppl.4-2015-025]                                                              
  miR-324-5p    Down           Increased N-Cadherin and E-Cadherin                                   [@b291-bmi-suppl.4-2015-025]                                                              
  n             miR-23b        Down                                                                  Increase of uPA--induces migration of human cervical cancer cells                         [@b264-bmi-suppl.4-2015-025]
  miR-34a       Down           Increased cell proliferation and transformation                       [@b265-bmi-suppl.4-2015-025]--[@b267-bmi-suppl.4-2015-025],[@b327-bmi-suppl.4-2015-025]   
  miR-203       Down           Increased cell proliferation                                          [@b268-bmi-suppl.4-2015-025]                                                              
  miR-218       Down           Deregulation of LAMB3--increased cell migration and tumorigenicity    [@b269-bmi-suppl.4-2015-025]                                                              
  miR-15a/16    Up             pRB degradation, altering c-myb, PPAR, c-myc levels                   [@b326-bmi-suppl.4-2015-025]                                                              
  miR-15b       Up             Reduced Cyclin E1--inhibits proliferation                             [@b288-bmi-suppl.4-2015-025]                                                              
  miR-203       Down           Blocks maPk/PkC; increases ∆Np63 activity--increases proliferation    [@b290-bmi-suppl.4-2015-025],[@b439-bmi-suppl.4-2015-025]                                 
  miR-205       Up             Decreases Akt pathway and Cyclin D1 levels--decreased proliferation   [@b289-bmi-suppl.4-2015-025]                                                              
  e6/e7         miR-21         Up                                                                    Targets CCL20--enhances tumorigenesis                                                     [@b440-bmi-suppl.4-2015-025]
  miR-24        Up             Decreases p27--increases proliferation                                [@b289-bmi-suppl.4-2015-025]                                                              

###### 

Selected miRNAs identified in HPV-associated conditions.

  CHANGE          miRNA                                                                   DISEASE/SOURCE                                                                                                        REFERENCES
  --------------- ----------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ------------------------------
  Upregulated     miR-15b                                                                 HPV+ cervical tissue                                                                                                  [@b286-bmi-suppl.4-2015-025]
  miR-16          HPV+ cervical tissue                                                    [@b286-bmi-suppl.4-2015-025]                                                                                          
  miR-21          HPV+ TSCC tissue                                                        [@b315-bmi-suppl.4-2015-025]                                                                                          
  miR-31          OSCC tissue (HPV±), HPV+ cervical cell lines                            [@b269-bmi-suppl.4-2015-025],[@b318-bmi-suppl.4-2015-025]                                                             
  miR-34c         HPV+ cervical cell lines                                                [@b269-bmi-suppl.4-2015-025]                                                                                          
  miR-146a        HPV16 E5-transfected keratinocytes                                      [@b291-bmi-suppl.4-2015-025]                                                                                          
  miR-181c        HPV+ keratinocytes                                                      [@b441-bmi-suppl.4-2015-025]                                                                                          
  miR-200c        HPV+ cervical cell lines                                                [@b269-bmi-suppl.4-2015-025]                                                                                          
  miR-203         HPV+ cervical cell lines                                                [@b269-bmi-suppl.4-2015-025]                                                                                          
  miR-205         HPV+ cervical tissue                                                    [@b286-bmi-suppl.4-2015-025]                                                                                          
  miR-363         HPV+ HNSCC cell lines, PSCC tissue (HPV±), HPV+ TSCC tissue             [@b315-bmi-suppl.4-2015-025],[@b318-bmi-suppl.4-2015-025],[@b319-bmi-suppl.4-2015-025]                                
  miR-497         HPV+ HNSCC cell lines                                                   [@b319-bmi-suppl.4-2015-025]                                                                                          
  Downregulated   miR-31                                                                  HPV+ TSCC tissue                                                                                                      [@b315-bmi-suppl.4-2015-025]
  miR-34a         HPV+ cell lines, HPV+ cervical tissues                                  [@b275-bmi-suppl.4-2015-025],[@b326-bmi-suppl.4-2015-025],[@b327-bmi-suppl.4-2015-025]                                
  miR-127-3p      PSCC tissue (HPV ±), HPV+ cervical tissue                               [@b318-bmi-suppl.4-2015-025],[@b442-bmi-suppl.4-2015-025]                                                             
  miR-143         HPV+ cervical tissue, HPV+ cervical cell lines                          [@b269-bmi-suppl.4-2015-025],[@b286-bmi-suppl.4-2015-025]                                                             
  miR-145         HPV+ cervical tissue, HPV+ cervical cell lines                          [@b269-bmi-suppl.4-2015-025],[@b286-bmi-suppl.4-2015-025]                                                             
  miR-155         HPV+ HNSCC cell lines                                                   [@b319-bmi-suppl.4-2015-025]                                                                                          
  miR-181a        HPV+ HNSCC cell lines                                                   [@b319-bmi-suppl.4-2015-025]                                                                                          
  miR-203         HPV16 E5-, E6-, or E7-transfected keratinocytes                         [@b290-bmi-suppl.4-2015-025],[@b291-bmi-suppl.4-2015-025]                                                             
  miR-218         HPV+ cervical cell lines, HPV+ HNSCC cell lines, HPV+ cervical tissue   [@b269-bmi-suppl.4-2015-025],[@b319-bmi-suppl.4-2015-025],[@b442-bmi-suppl.4-2015-025],[@b443-bmi-suppl.4-2015-025]   
  miR-324-5p      HPV16 E5-transfected keratinocytes                                      [@b291-bmi-suppl.4-2015-025]                                                                                          
  miR-375         OSCC tissue (HPV±)                                                      [@b318-bmi-suppl.4-2015-025]                                                                                          

###### 

Biomarker potential of host miRNAs associated with HIV-1 infection (\>2-fold change in miRNA): selected studies.

  SAMPLE TYPE                                   miRNA UPREGULATED                        miRnA DOWNREGULATED                                                                                        REFERENCES
  --------------------------------------------- ---------------------------------------- ---------------------------------------------------------------------------------------------------------- ------------------------------
  HIV-infected CD4+CD8-PBMCs                    miR-223                                  miR-29a/b, miR-155, miR-21                                                                                 [@b446-bmi-suppl.4-2015-025]
  HIV-infected Jurkat cells                     miR-122, miR-297, miR-370, miR-373^\*^   miR17/92 cluster                                                                                           [@b339-bmi-suppl.4-2015-025]
  PBMCs from HIV-infected patients                                                       miR-15b, miR-23a, miR-23b, miR-26a, miR27a, miR-92, miR-144, miR-210, miR-320, miR-337, miR-342, miR-451   447
  PBMCs from HIV-infected patients              miR-9, mirR-181b                         miR-31, miR-31\*, let-7g, miR-125b, miR-150                                                                [@b350-bmi-suppl.4-2015-025]
  Plasma and PBMCs from HIV-infected patients   miR-150, miR-146b-5p                                                                                                                                [@b349-bmi-suppl.4-2015-025]

[^1]: These authors contributed equally to this work.
